

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	"7064217".pn.	USPAT; DERWENT	OR	ON	2006/09/26 14:39
L2	2	"6069251".pn.	USPAT; DERWENT	OR	ON	2006/09/26 14:41
L3	2	"5405988".pn.	USPAT; DERWENT	OR	ON	2006/09/26 14:41
L4	2	"4939130".pn.	USPAT; DERWENT	OR	ON	2006/09/26 14:41
L5	1356	548/112,340.1;514/400.CCLS.	USPAT; DERWENT	OR	ON	2006/09/26 16:34
L6	2	I5 and phospate	USPAT; DERWENT	OR	ON	2006/09/26 16:35
L7	1	I5 and phosponate	USPAT; DERWENT	OR	ON	2006/09/26 16:36
L8	137	I5 and phosphonate	USPAT; DERWENT	OR	ON	2006/09/26 16:36
L9	50	I8 and imidazol	USPAT; DERWENT	OR	ON	2006/09/26 16:36

Andrew Freistein 10/523,337

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPplus enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPplus and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPplus
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPplus(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPplus enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPplus fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/CAPplus(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS EXPRESS		JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Andrew Freistein 10/523,337

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:23:58 ON 26 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:24:19 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10523337\c.str



```
chain nodes :
12 13 14 17 18
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
3-6 5-12 12-14 12-13 12-17 17-18
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 12-14 12-13
exact bonds :
3-6 5-12 12-17 17-18
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
```

G1:H,Ak


```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 17:CLASS 18:CLASS
```

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:24:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 521 TO ITERATE

100.0% PROCESSED 521 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 9051 TO 11789

PROJECTED ANSWERS: 146 TO 694

L2 21 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:24:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 10014 TO ITERATE

100.0% PROCESSED 10014 ITERATIONS

380 ANSWERS

SEARCH TIME: 00.00.01

L3 380 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 12:24:50 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Andrew Freistein 10/523,337

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 38 L3

=> d 5

Andrew Freistein 10/523,337

L4 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:589369 CAPLUS
DN 143:248595
TI Synthesis of 4(5)-phenylimidazole-based analogs of
sphingosine-1-phosphate
and FTY720: Discovery of potent S1P1 receptor agonists
AU Clemens, Jeremy J.; Davis, Michael D.; Lynch, Kevin R.; Macdonald,
Timothy
L.
CS Department of Chemistry, University of Virginia, Charlottesville, VA, USA
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(15), 3568-3572
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 143:248595
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Andrew Freistein 10/523,337

=> s l4 and py<2003

22828390 PY<2003

L5 28 L4 AND PY<2003

=> d ibib

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2005:140811 CAPLUS
 DOCUMENT NUMBER: 142:240429
 TITLE: Five-membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments
 INVENTOR(S): Chabrier De Lassauniere, Pierre-etienne; Harnett, Jeremiah; Bigg, Dennis; Liberatore, Ann-Marie;
 Pommier, Jacques; Lannoy, Jacques; Thuriereau, Christophe; Dong, Zheng Xin
 PATENT ASSIGNEE(S): Fr.
 SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. 681,002.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005038087	A1	20050217	US 2004-915001	20040810
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1589007	A2	20051026	EP 2005-76749	20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY				
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
WO 2002083656	A2	20021024	WO 2002-FR1218	20020409
WO 2002083656	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, SF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 ZA 2003007750 A 20040726 ZA 2003-7750 20031003
 US 2004132788 A1 20040708 US 2003-681002 20031008
 WO 2005035510 A1 20050421 WO 2004-FR2537 20041008
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1675836 A1 20060705 EP 2004-791489 20041008
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 PRIORITY APPLN. INFO.: FR 1999-12643 A 19991011
 FR 2000-10151 A 20000801
 FR 2000-11169 A 20000901
 WO 2000-FR2805 W 20001010
 FR 2001-4943 A 20010410
 FR 2002-1811 A 20020214
 US 2002-89993 A2 20020404
 WO 2002-FR1218 A1 20020409
 US 2003-681002 A2 20031008
 EP 2000-967988 A3 20001010
 US 2004-915001 A 20040810
 WO 2004-FR2537 W 20041008

OTHER SOURCE(S): MARPAT 142:240429

Andrew Freistein 10/523,337


=> d hitstr

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 335246-82-7P, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 335246-82-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




IT 252279-09-7, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-59-8, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 252279-09-7 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-59-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 fluorophenyl)-1H-imidazol-2-yl]ethylamine hydrochloride 335245-72-2P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335245-88-0P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine hydrochloride 335246-39-4P, 1-Methyl-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-49-6P, (1R)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine 335246-57-6P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-83-8P, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-2-cyclohexylethanamine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 167983-80-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-08-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, α , α -dimethyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335243-12-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, hydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

IT 167983-80-4P, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 335243-08-6P, 1-Methyl-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-12-4P, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335243-21-5P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine hydrochloride 335243-25-9P, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335243-44-2P, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-45-3P, (1R)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine hydrochloride 335243-46-4P, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-47-5P, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-51-1P, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-60-2P, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335243-72-6P, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-81-7P, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine hydrochloride 335243-82-8P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-92-0P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine hydrochloride 335244-11-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-2-cyclohexylethanamine hydrochloride 335244-27-4P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-3-phenyl-1-propanamine hydrochloride 335244-36-5P, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pentanamine hydrochloride 335244-42-3P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)pentylamine hydrochloride 335244-45-6P, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-46-7P, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-49-0P, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-51-4P, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-52-5P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-58-1P, (1S)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-propanamine hydrochloride 335244-61-6P, (1S)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-1-propanamine hydrochloride 335244-67-2P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile hydrochloride 335244-68-3P, (R,S)-1-[4-(4-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-71-8P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-butanamine hydrochloride 335244-72-9P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol hydrochloride 335244-73-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335244-80-9P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335244-81-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335244-82-1P, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-83-2P, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-93-4P, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-95-6P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine hydrochloride 335245-17-5P, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-




● x HCl

RN 335243-21-5 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335243-25-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-44-2 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335243-45-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4,5-diphenyl-1H-imidazol-2-yl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 335243-46-4 CAPLUS
CN 1H-Indazole-2-methanamine, 4-phenyl- α -(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-47-5 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-81-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 335243-82-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 335243-92-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl

RN 335243-51-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 335243-60-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 335243-72-6 CAPLUS


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl

RN 335244-11-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(cyclohexylmethyl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 335244-27-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


RN 335244-36-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -butyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-42-3 CAPLUS
CN 1H-imidazole-2-methanamine, α-butyl-4-phenyl-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl


RN 335244-45-6 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-46-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●x HCl

RN 335244-58-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335244-61-6 CAPLUS
CN 1H-imidazole-2-methanamine, α-ethyl-4,5-diphenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335244-67-2 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-49-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-51-4 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-52-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-68-3 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 335244-71-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-propyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335244-72-9 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335244-73-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl-α-propyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 335244-80-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335244-81-0 CAPLUS
CN 1H-imidazole-2-methanamine, α-methyl-4-phenyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335244-95-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335245-17-5 CAPLUS
CN 1H-indole-3-ethanamine, 5-fluoro-α-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335245-72-2 CAPLUS
CN 1H-imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335244-82-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-83-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-93-4 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335245-88-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 335246-39-4 CAPLUS
CN 1H-imidazole-2-methanamine, α,α-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-49-6 CAPLUS
CN 1H-indole-3-ethanamine, α-(4,5-diphenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-57-6 CAPLUS
CN 1H-Indazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-,
(α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-83-8 CAPLUS
CN 1H-Indazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)



RN 335247-08-0 CAPLUS
CN 1H-Indazole-2-methanamine, α -(cyclohexylmethyl)-4-(4-fluorophenyl)-,
(α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-14-8 CAPLUS


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

335246-81-6, (1R)-1-[4-(4-Phenyl-1H-imidazol-2-yl)ethanamine]
335246-87-2, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-
heptanamine 335246-91-8, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(
4-fluorophenyl)-1H-imidazol-2-yl]ethanamine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(drug candidate; prepn. of five-membered heterocycle derivs. as MAO
inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 252279-15-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-nitrophenyl)-1H-imidazol-2-yl]-,
(α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-23-6 CAPLUS
CN Phenol,
4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-
(9CI) (CA INDEX NAME)




RN 335246-41-8 CAPLUS
CN 1H-Indazole-2-methanamine, α -pentyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-42-9 CAPLUS
CN 1H-Indazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Indazole-2-methanamine, 4-(4-fluorophenyl)- α -(phenylmethyl)-,
(α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS
CN 1H-Indazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -
(cyclohexylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252279-15-5, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 335246-23-6, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol 335246-41-8, (R,S)-1-[4-(4-Phenyl-1H-imidazol-2-yl)hexylamine 335246-42-9, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-48-5, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine 335246-50-9, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-51-0, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-54-3, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-56-5, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine 335246-67-8, (1R)-1-[4-(1,1'-Biphenyl)-4-yl]-1H-imidazol-2-yl]-3-phenyl-1-propanamine 335246-69-0, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-70-3, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]-1-heptylamine 335246-71-4, (R,S)-1-[4-(1,1'-Biphenyl)-4-yl]-1H-imidazol-2-yl]-1-heptanamine 335246-72-5, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-73-6, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-74-7, (1S)-1-[4-(1,1'-Biphenyl)-4-yl]-1H-imidazol-2-yl]-1-propanamine 335246-75-8, (1S)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-1-propanamine 335246-77-0, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile 335246-78-1, (1R)-1-[4-(1,1'-Biphenyl)-4-yl]-1H-imidazol-2-yl]-1-butanamine 335246-79-2, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine 335246-80-5, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-48-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)



RN 335246-50-9 CAPLUS
CN 1H-Indazole-2-methanamine, 4-phenyl- α -(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-56-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-67-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-69-0 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335246-70-3 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-75-8 CAPLUS
CN 1H-imidazole-2-methanamine, α-ethyl-4,5-diphenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 335246-78-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-propyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-71-4 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-, (αS)- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-, (αS)- (9CI) (CA INDEX NAME)




RN 335246-74-7 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-80-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-, (αS)- (9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS
CN 1H-imidazole-2-methanamine, α-methyl-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-87-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-, (αS)- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS
CN 1H-indole-3-ethanamine, 5-fluoro-α-(4-(4-fluorophenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 335247-34-2P, 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 335247-34-2 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- α -(4-methylpentyl)- (9CI) (CA INDEX NAME)



IT 717915-66-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 717915-66-7 CAPLUS
 CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)




Andrew Freistein 10/523,337

=> d ibib abs hitstr 2-28

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:550745 CAPLUS
 DOCUMENT NUMBER: 141:106475
 TITLE: Preparation of 5-membered heterocycle derivatives for treating neurodegenerative disorders or pain
 INVENTOR(S): Chabrier De Lessauliere, Pierre-Etienne; Harnett, Jeremiah; Biggs, Dennis; Liberatore, Anne-Marie; Pommier, Jacques; Lannoy, Jacques; Thuriel, Christophe
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S. Ser. No. 89,993.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RN: GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1589007	A2	20051026	EP 2005-76749	20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY				
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
ZA 2003007750	A	20040726	ZA 2003-7750	20031003
US 2005038087	A1	20050217	US 2004-915001	20040810
WO 2005035510	A1	20050421	WO 2004-FR2537	20041008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,				


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 alkyl, cycloalkyl; Q = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl].
 These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipid peroxidn. and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus,
 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]amino]ethanethioamide (4.3 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atm. and stirred at ambient temp. for 12 h to give, after workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[[[(1,1-dimethylethoxy)carbonyl]-N-methyl-2-thiazolemethanamine which was treated with CF3CO2H and triethylsilane in 50 mL CH2Cl2 to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC50 of lower than 10 µM for inhibiting lipid peroxidn. of the cerebral cortex of rats.
 IT 252279-09-7P, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-59-8P 335246-82-7P 335247-34-2P, 1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (intermediate; preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)
 RN 252279-09-7 CAPLUS
 CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 335246-59-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued).
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1675836 A1 20060705 EP 2004-791489 20041008
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 PRIORITY APPLN. INFO.: FR 1999-12643 A 19991011
 FR 2000-10151 A 20000801
 FR 2000-11169 A 20000901
 WO 2000-FR2805 W 20001010
 FR 2001-4943 A 20010410
 FR 2002-1811 A 20020214
 US 2002-89993 A2 20020404
 EP 2000-967988 A3 20001010
 WO 2002-FR1218 A1 20020409
 US 2003-681002 A2 20031008
 US 2004-915001 A 20040810
 WO 2004-FR2537 W 20041008

OTHER SOURCE(S): MARPAT 141:106475
 GI




AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) [wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph; R1, R2 = H,


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 335246-82-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)



RN 335247-34-2 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)



IT 167983-80-4P 252279-15-5P, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 335243-08-8P, [1-Methyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amine hydrochloride 335243-45-3P, (1R)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine hydrochloride 335243-51-1P, (1R)-2-[1H-Indol-3-yl]-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-60-2P, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335244-11-6P, (1R)-1-[4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-2-cyclohexylethanamine hydrochloride 335244-68-3P 335246-23-6P 335246-39-4P, [1-Methyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amine 335246-41-8P 335246-42-9P 335246-48-5P 335246-49-6P 335246-50-9P 335246-51-0P 335246-54-3P 335246-56-5P 335246-57-6P 335246-67-8P 335246-69-0P 335246-70-3P 335246-71-4P 335246-72-5P 335246-73-6P 335246-74-7P 335246-75-8P 335246-77-0P 335246-78-1P 335246-79-2P 335246-80-5P 335246-81-6P 335246-83-8P 335246-87-2P 335246-91-8P 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-2-cyclohexylethanamine 335247-28-7P 335247-29-8P 335247-30-2P 335247-31-9P 335247-32-4P 335247-33-1P 335247-34-2P 335247-35-3P 335247-36-4P 335247-37-5P 335247-38-6P 335247-39-7P 335247-40-8P 335247-41-9P 335247-42-0P 335247-43-1P 335247-44-2P 335247-45-3P 335247-46-4P 335247-47-5P 335247-48-6P 335247-49-7P 335247-50-8P 335247-51-9P 335247-52-0P 335247-53-1P 335247-54-2P 335247-55-3P 335247-56-4P 335247-57-5P 335247-58-6P 335247-59-7P 335247-60-8P 335247-61-9P 335247-62-0P 335247-63-1P 335247-64-2P 335247-65-3P 335247-66-4P 335247-67-5P 335247-68-6P 335247-69-7P 335247-70-8P 335247-71-9P 335247-72-0P 335247-73-1P 335247-74-2P 335247-75-3P 335247-76-4P 335247-77-5P 335247-78-6P 335247-79-7P 335247-80-8P 335247-81-9P 335247-82-0P 335247-83-1P 335247-84-2P 335247-85-3P 335247-86-4P 335247-87-5P 335247-88-6P 335247-89-7P 335247-90-8P 335247-91-9P 335247-92-0P 335247-93-1P 335247-94-2P 335247-95-3P 335247-96-4P 335247-97-5P 335247-98-6P 335247-99-7P 335248-00-8P 335248-01-9P 335248-02-0P 335248-03-1P 335248-04-2P 335248-05-3P 335248-06-4P 335248-07-5P 335248-08-6P 335248-09-7P 335248-10-8P 335248-11-9P 335248-12-0P 335248-13-1P 335248-14-2P 335248-15-3P 335248-16-4P 335248-17-5P 335248-18-6P 335248-19-7P 335248-20-8P 335248-21-9P 335248-22-0P 335248-23-1P 335248-24-2P 335248-25-3P 335248-26-4P 335248-27-5P 335248-28-6P 335248-29-7P 335248-30-8P 335248-31-9P 335248-32-0P 335248-33-1P 335248-34-2P 335248-35-3P 335248-36-4P 335248-37-5P 335248-38-6P 335248-39-7P 335248-40-8P 335248-41-9P 335248-42-0P 335248-43-1P 335248-44-2P 335248-45-3P 335248-46-4P 335248-47-5P 335248-48-6P 335248-49-7P 335248-50-8P 335248-51-9P 335248-52-0P 335248-53-1P 335248-54-2P 335248-55-3P 335248-56-4P 335248-57-5P 335248-58-6P 335248-59-7P 335248-60-8P 335248-61-9P 335248-62-0P 335248-63-1P 335248-64-2P 335248-65-3P 335248-66-4P 335248-67-5P 335248-68-6P 335248-69-7P 335248-70-8P 335248-71-9P 335248-72-0P 335248-73-1P 335248-74-2P 335248-75-3P 335248-76-4P 335248-77-5P 335248-78-6P 335248-79-7P 335248-80-8P 335248-81-9P 335248-82-0P 335248-83-1P 335248-84-2P 335248-85-3P 335248-86-4P 335248-87-5P 335248-88-6P 335248-89-7P 335248-90-8P 335248-91-9P 335248-92-0P 335248-93-1P 335248-94-2P 335248-95-3P 335248-96-4P 335248-97-5P 335248-98-6P 335248-99-7P 335249-00-8P 335249-01-9P 335249-02-0P 335249-03-1P 335249-04-2P 335249-05-3P 335249-06-4P 335249-07-5P 335249-08-6P 335249-09-7P 335249-10-8P 335249-11-9P 335249-12-0P 335249-13-1P 335249-14-2P 335249-15-3P 335249-16-4P 335249-17-5P 335249-18-6P 335249-19-7P 335249-20-8P 335249-21-9P 335249-22-0P 335249-23-1P 335249-24-2P 335249-25-3P 335249-26-4P 335249-27-5P 335249-28-6P 335249-29-7P 335249-30-8P 335249-31-9P 335249-32-0P 335249-33-1P 335249-34-2P 335249-35-3P 335249-36-4P 335249-37-5P 335249-38-6P 335249-39-7P 335249-40-8P 335249-41-9P 335249-42-0P 335249-43-1P 335249-44-2P 335249-45-3P 335249-46-4P 335249-47-5P 335249-48-6P 335249-49-7P 335249-50-8P 335249-51-9P 335249-52-0P 335249-53-1P 335249-54-2P 335249-55-3P 335249-56-4P 335249-57-5P 335249-58-6P 335249-59-7P 335249-60-8P 335249-61-9P 335249-62-0P 335249-63-1P 335249-64-2P 335249-65-3P 335249-66-4P 335249-67-5P 335249-68-6P 335249-69-7P 335249-70-8P 335249-71-9P 335249-72-0P 335249-73-1P 335249-74-2P 335249-75-3P 335249-76-4P 335249-77-5P 335249-78-6P 335249-79-7P 335249-80-8P 335249-81-9P 335249-82-0P 335249-83-1P 335249-84-2P 335249-85-3P 335249-86-4P 335249-87-5P 335249-88-6P 335249-89-7P 335249-90-8P 335249-91-9P 335249-92-0P 335249-93-1P 335249-94-2P 335249-95-3P 335249-96-4P 335249-97-5P 335249-98-6P 335249-99-7P 335250-00-8P 335250-01-9P 335250-02-0P 335250-03-1P 335250-04-2P 335250-05-3P 335250-06-4P 335250-07-5P 335250-08-6P 335250-09-7P 335250-10-8P 335250-11-9P 335250-12-0P 335250-13-1P 335250-14-2P 335250-15-3P 335250-16-4P 335250-17-5P 335250-18-6P 335250-19-7P 335250-20-8P 335250-21-9P 335250-22-0P 335250-23-1P 335250-24-2P 335250-25-3P 335250-26-4P 335250-27-5P 335250-28-6P 335250-29-7P 335250-30-8P 335250-31-9P 335250-32-0P 335250-33-1P 335250-34-2P 335250-35-3P 335250-36-4P 335250-37-5P 335250-38-6P 335250-39-7P 335250-40-8P 335250-41-9P 335250-42-0P 335250-43-1P 335250-44-2P 335250-45-3P 335250-46-4P 335250-47-5P 335250-48-6P 335250-49-7P 335250-50-8P 335250-51-9P 335250-52-0P 335250-53-1P 335250-54-2P 335250-55-3P 335250-56-4P 335250-57-5P 335250-58-6P 335250-59-7P 335250-60-8P 335250-61-9P 335250-62-0P 335250-63-1P 335250-64-2P 335250-65-3P 335250-66-4P 335250-67-5P 335250-68-6P 335250-69-7P 335250-70-8P 335250-71-9P 335250-72-0P 335250-73-1P 335250-74-2P 335250-75-3P 335250-76-4P 335250-77-5P 335250-78-6P 335250-79-7P 335250-80-8P 335250-81-9P 335250-82-0P 335250-83-1P 335250-84-2P 335250-85-3P 335250-86-4P 335250-87-5P 335250-88-6P 335250-89-7P 335250-90-8P 335250-91-9P 335250-92-0P 335250-93-1P 335250-94-2P 335250-95-3P 335250-96-4P 335250-97-5P 335250-98-6P 335250-99-7P 335251-00-8P 335251-01-9P 335251-02-0P 335251-03-1P 335251-04-2P 335251-05-3P 335251-06-4P 335251-07-5P 335251-08-6P 335251-09-7P 335251-10-8P 335251-11-9P 335251-12-0P 335251-13-1P 335251-14-2P 335251-15-3P 335251-16-4P 335251-17-5P 335251-18-6P 335251-19-7P 335251-20-8P 335251-21-9P 335251-22-0P 335251-23-1P 335251-24-2P 335251-25-3P 335251-26-4P 335251-27-5P 335251-28-6P 335251-29-7P 335251-30-8P 335251-31-9P 335251-32-0P 335251-33-1P 335251-34-2P 335251-35-3P 335251-36-4P 335251-37-5P 335251-38-6P 335251-39-7P 335251-40-8P 335251-41-9P 335251-42-0P 335251-43-1P 335251-44-2P 335251-45-3P 335251-46-4P 335251-47-5P 335251-48-6P 335251-49-7P 335251-50-8P 335251-51-9P 335251-52-0P 335251-53-1P 335251-54-2P 335251-55-3P 335251-56-4P 335251-57-5P 335251-58-6P 335251-59-7P 335251-60-8P 335251-61-9P 335251-62-0P 335251-63-1P 335251-64-2P 335251-65-3P 335251-66-4P 335251-67-5P 335251-68-6P 335251-69-7P 335251-70-8P 335251-71-9P 335251-72-0P 335251-73-1P 335251-74-2P 335251-75-3P 335251-76-4P 335251-77-5P 335251-78-6P 335251-79-7P 335251-80-8P 335251-81-9P 335251-82-0P 335251-83-1P 335251-84-2P 335251-85-3P 335251-86-4P 335251-87-5P 335251-88-6P 335251-89-7P 335251-90-8P 335251-91-9P 335251-92-0P 335251-93-1P 335251-94-2P 335251-95-3P 335251-96-4P 335251-97-5P 335251-98-6P 335251-99-7P 335252-00-8P 335252-01-9P 335252-02-0P 335252-03-1P 335252-04-2P 335252-05-3P 335252-06-4P 335252-07-5P 335252-08-6P 335252-09-7P 335252-10-8P 335252-11-9P 335252-12-0P 335252-13-1P 335252-14-2P 335252-15-3P 335252-16-4P 335252-17-5P 335252-18-6P 335252-19-7P 335252-20-8P 335252-21-9P 335252-22-0P 335252-23-1P 335252-24-2P 335252-25-3P 335252-26-4P 335252-27-5P 335252-28-6P 335252-29-7P 335252-30-8P 335252-31-9P 335252-32-0P 335252-33-1P 335252-34-2P 335252-35-3P 335252-36-4P 335252-37-5P 335252-38-6P 335252-39-7P 335252-40-8P 335252-41-9P 335252-42-0P 335252-43-1P 335252-44-2P 335252-45-3P 335252-46-4P 335252-47-5

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

717914-33-5P 717914-34-6P 717914-35-7P
 717914-36-8P 717914-37-9P 717914-38-0P
 717914-39-1P 717914-42-6P 717914-43-7P
 717914-45-9P 717914-46-0P 717914-47-1P
 717914-48-2P 717914-50-6P 717914-51-7P
 717914-52-8P 717914-53-9P 717914-59-5P
 717914-60-8P 717914-64-2P 717914-71-1P
 717914-74-4P 717915-66-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 167983-80-4 CAPLUS

CN 1H-imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-15-5 CAPLUS

CN 1H-Indole-3-ethanamine, α -[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-08-8 CAPLUS

CN 1H-Imidazole-2-methanamine, α , α -dimethyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335244-11-6 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(cyclohexylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 335244-68-3 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)- α -hexyl-, (9CI) (CA INDEX NAME)



RN 335246-23-6 CAPLUS

CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335243-45-3 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4,5-diphenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335243-51-1 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335243-60-2 CAPLUS


CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-,

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-39-4 CAPLUS

CN 1H-Imidazole-2-methanamine, α , α -dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-41-8 CAPLUS

CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS

CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 335246-48-5 CAPLUS


CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 335246-49-6 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4,5-diphenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-50-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)




RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl- (9CI) (CA INDEX NAME)



RN 335246-74-7 CAPLUS


09/26/2006

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-56-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-57-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-67-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-69-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-75-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -ethyl-4,5-diphenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, (αR)- (9CI)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 396135-27-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl- (9CI) (CA INDEX NAME)




RN 396135-28-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 717914-13-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 717914-14-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335247-08-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-14-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(cyclohexylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 717914-16-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-21-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-22-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 717914-23-3 CAPLUS
CN 1H-indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-25-5 CAPLUS
CN 1H-indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-28-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 717914-33-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-34-6 CAPLUS
CN 1H-imidazole-2-methanamine, α-butyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-35-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 717914-29-9 CAPLUS
CN 1H-imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 717914-30-2 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-32-4 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 717914-36-8 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-37-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-38-0 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 717914-39-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-42-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, monohydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 717914-43-7 CAPLUS
CN 1H-imidazole-2-methanamine, α -ethyl-4,5-diphenyl-, monohydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 717914-48-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl- α -propyl-, monohydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 717914-50-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-51-7 CAPLUS
CN 1H-imidazole-2-methanamine, α -methyl-4-phenyl-, monohydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-52-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 717914-45-9 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-46-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, monohydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 717914-47-1 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 717914-53-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-54-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-59-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-60-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- α -(4-methylpentyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 717914-64-2 CAPLUS
CN 1H-Indole-2-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-71-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 717914-74-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:107321 CAPLUS
DOCUMENT NUMBER: 136:167373
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors
INVENTOR(S): Thurlieu, Christophe Alain; Poltout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry
PATENT ASSIGNEE(S): A.; Moynet, Christophe Philippe; Bigg, Dennis Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 369 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010140	A2	20020207	WO 2001-US23959	20010731
WO 2002010140	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GH, GG, GW, ML, MR, NE, SN, TD, TG			
CA 2417204	AA	20020207	CA 2001-2417204	20010731
EP 1305294	A2	20030502	EP 2001-957342	20010731
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004518613	T2	20040624	JP 2002-516272	20010731
NZ 523774	A	20040924	NZ 2001-523774	20010731
NO 2003000473	A	20030130	NO 2003-473	20030130
PRIORITY APPLN. INFO.:			US 2000-222584P	P 20000801
			WO 2001-US23959	W 20010731
OTHER SOURCE(S):	MARPAT 136:167373			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Imidazole deriva. I [R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; m = 0-6; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mAl; Al = C(:Y)NX1X2; C(:Y)X2; C(:NH)X2, X2: Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.], which are useful as

L5 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 717915-66-7 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepd. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addn. of 2-[(1S)-1-amino-2-(indol-3-yl)ethyl]-4-phenyl-1H-imidazole afforded 94% the title compd. V. Compds. I are effective at 0.01-10.0 mg/kg/day.


IT RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 335246-59-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-82-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335247-34-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)



IT 167983-80-4P 252279-15-5P 335243-12-4P
335243-21-5P 335243-25-9P 335243-44-2P
335243-46-4P 335243-47-5P 335243-51-1P
335243-60-2P 335243-72-6P 335243-81-7P
335243-92-0P 335244-27-4P 335244-36-5P
335244-42-3P 335244-45-6P 335244-46-7P
335244-49-0P 335244-51-4P 335244-52-5P
335244-58-1P 335244-67-2P 335244-68-3P
335244-71-8P 335244-72-9P 335244-73-0P
335244-80-9P 335244-81-0P 335244-82-1P
335244-83-2P 335244-93-4P 335244-95-6P
335245-17-5P 335246-23-6P 335246-41-8P
335246-42-9P 335246-48-5P 335246-50-9P


L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 335246-51-0P 335246-54-3P 335246-56-5P
 335246-67-8P 335246-69-0P 335246-70-3P
 335246-71-4P 335246-72-5P 335246-73-6P
 335246-74-7P 335246-77-0P 335246-78-1P
 335246-79-2P 335246-80-5P 335246-81-6P
 335246-83-8P 335246-87-2P 335246-91-8P
 396135-27-6P 396135-28-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of imidazolyl derivs. as agonists or antagonists of
 somatostatin receptors)
 RN 167983-80-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-,
 (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-15-5 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-,
 (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-12-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-,
 hydrochloride, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335243-21-5 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl-, hydrochloride (9CI)
 (CA INDEX NAME)



● x HCl


RN 335243-25-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-,
 hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335243-44-2 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-,
 hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335243-46-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(phenylmethyl)-,
 hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-47-5 CAPLUS
 CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)-,
 hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335243-51-1 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-,
 hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335243-60-2 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-,
 hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 335243-72-6 CAPLUS
 CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)-,
 hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335243-81-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-,
 hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●x HCl


RN 335243-92-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl

RN 335244-27-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335244-36-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-49-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-51-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-52-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


09/26/2006

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-42-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl

RN 335244-45-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-46-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 335244-58-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-67-2 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)



●x HCl


RN 335244-68-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 335244-71-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-propyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335244-72-9 CAPLUS
CN Phenol,
4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-
hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-73-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl-α-propyl-, hydrochloride,
(αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


RN 335244-80-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-,
hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335244-93-4 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-,
hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-95-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-,
hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335245-17-5 CAPLUS
CN 1H-indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-,
hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335244-81-0 CAPLUS
CN 1H-imidazole-2-methanamine, α-methyl-4-phenyl-, hydrochloride,
(αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 335244-82-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-,
hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-83-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-,
hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl


RN 335246-23-6 CAPLUS
CN Phenol,
4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-
(9CI) (CA INDEX NAME)



RN 335246-41-8 CAPLUS
CN 1H-imidazole-2-methanamine, α-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-48-5 CAPLUS
CN 1H-indole-3-ethanamine, α-(4-methyl-5-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-50-9 CAPLUS
CN 1H-Indazole-2-methanamine, 4-phenyl-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-51-0 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-56-5 CAPLUS
CN 1H-Indazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-74-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-67-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-69-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-87-2 CAPLUS
CN 1H-Indole-3-ethanamine, 4-(3,4-dichlorophenyl)-α-hexyl- (9CI)
(CA INDEX NAME)



RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 396135-27-6 CAPLUS
CN 1H-Indole-3-ethanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl- (9CI)
(CA INDEX NAME)



RN 396135-28-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-butyl-4-phenyl- (9CI) (CA INDEX NAME)


L5 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:527784 CAPLUS
DOCUMENT NUMBER: 135:251427
TITLE: Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity
AUTHOR(S): Poitout, Lydie; Roubert, Pierre; Contour-Galceran, Marie-Odile; Molinet, Christophe; Lannoy, Jacques; Pommer, Jacques; Plas, Pascale; Bigg, Dennis; Thureau, Christophe
CORPORATE SOURCE: Institut Henri Beaufour, Les Ulis, F-91966, Fr.
SOURCE: Journal of Medicinal Chemistry (2001), 44(18), 2990-3000
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:251427
AB Using a solution-phase parallel synthesis strategy, a series of non-peptide somatostatin analogs were prepared, and their binding affinities to the five human somatostatin receptor subtypes (sst1-5) were determined. Imidazolyl derivs. were found to bind with moderate affinity but with high selectivity to the sst3 receptor subtype. Further modifications of these structures led to a more potent class of ligands, the tetrahydro-β-carboline derivs. Among these, compds. BN81644 and BN81674 bind selectively and with high affinity to the sst3 receptor subtype (K_i = 0.64 and 0.92 nM, resp.). Furthermore, BN81644 and BN81674 reverse the inhibition of cAMP accumulation induced by 1 nM somatostatin via sst3 receptors, with IC₅₀ = 2.7 and 0.84 nM, resp. The most potent compound BN81674 was shown to be a competitive antagonist of human sst3 receptors by increasing the EC₅₀ of SRIF-14-mediated inhibition of cAMP accumulation with a KB of 2.8 nM (where KB is the concentration of antagonist that shifts the agonist dose-response 2-fold). These new derivs. are, to the authors knowledge, the first potent and highly selective non-peptide human sst3 antagonists known and, as such, are useful tools for investigating the physiol. role of sst3 receptors.

IT 252279-08-6P 252279-09-7P 361576-63-8P
361576-64-9P 361576-65-0P 361576-66-1P
361576-67-2P 361576-68-3P 361576-69-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Identification of potent non-peptide somatostatin receptor antagonists with sst3 selectivity)
RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 252279-08-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252279-09-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 361576-63-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 361576-64-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 361576-65-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-5-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 361576-66-1 CAPLUS
CN 1H-Indole-3-ethanamine, 5-methyl- α -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 361576-67-2 CAPLUS
CN 1H-Indole-3-ethanamine, 5-chloro- α -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L5 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

RN 361576-68-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4,5-diphenyl-1H-imidazol-2-yl)-, dihydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 361576-69-4 CAPLUS
CN 1H-imidazole-2-methanamine, α -(benzo[b]thien-3-ylmethyl)-4-phenyl-, dihydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS


L5 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:396863 CAPLUS
DOCUMENT NUMBER: 135:19656
TITLE: Preparation of 4-[pyridin-4-yl]-(or pyrimidin-4-yl)-1H-imidazoles as B-Raf kinase inhibitors
INVENTOR(S): Dean, David Kenneth; Lovell, Peter John; Takle, Andrew
PATENT ASSIGNEE(S): Kenneth Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038324	A2	20010531	WO 2000-GB4413	20001120
<--				
WO 2001038324	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1232153	A2	20020821	EP 2000-977660	20001120
<--				
EP 1232153	B1	20041103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200201364	T2	20021021	TR 2002-1364	20001120
<--				
JP 2003514906	T2	20030422	JP 2001-540087	20001120
CN 1543346	A	20041103	CN 2000-815949	20001120
AT 281451	E	20041115	AT 2000-977660	20001120
ES 2228629	T3	20050416	ES 2000-977660	20001120
ZA 2002003987	A	20031125	ZA 2002-3987	20020520
US 7026336	B1	20060411	US 2002-130019	20020923
PRIORITY APPLN. INFO.:				
			US 1999-166814P	P 19991122
			US 1999-166885P	P 19991122
			US 1999-166886P	P 19991122
			US 1999-166895P	P 19991122
			WO 2000-GB4413	W 20001120

OTHER SOURCE(S): MARPAT 135:19656
G1

L5 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title compds. [I; X = O, CH₂, S, NH, or XR1 = H; V = CH, N; Y = NR1OR11, NR1OC(:Z)NR1OR11, NR1OSO2R11; Ar = (un)substituted Ph, 5-6 membered heteroaryl; n = 0-4; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, or R2 and R3 together with the carbon atom to which they are attached form (un)substituted cycloalkyl, cycloalkenyl, 5-7 membered heterocyclyl; R4 = H, halo, etc.; R10, R11 = H, alkyl, etc.; Z = O, S], useful as B-Raf kinase inhibitors for the treatment of neurotraumatic diseases, were prepared. E.g., a multi-step synthesis of I [XR1 = H; V =

CH: Y = NHCO₂tBu; n = 1; Ar = 4-Cl-3-MeOC₆H₃; R2, R3 = Me; R4 = H] was given. The exemplified compds. I were found to be effective in inhibiting B-Raf mediated phosphorylation of GST-kdMEK substrate having IC₅₀'s of < 3 μM.

IT 342434-67-7P
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
[preparation of 4-(pyridin-4-yl)(or pyrimidin-4-yl)-1H-imidazoles as

B-Raf kinase inhibitors)
RN 342434-67-7 CAPLUS

CN Phenol, 5-[2-(1-amino-1-methylethyl)-5-(4-pyridinyl)-1H-imidazol-4-yl]-2-chloro- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

NZ 518304	A	20040730	NZ 2000-518304	20001010
NZ 533429	A	20040924	NZ 2000-533429	20001010
AU 783129	B2	20050929	AU 2000-77965	20001010
EP 1589007	A2	20051026	EP 2005-76749	20001010

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY

RU 2271355 C2 20060310 RU 2002-112227 20001010
NO 2002001689 A 20020530 NO 2002-1689 20020410

-- US 2004132788 A1 20040708 US 2003-681002 20031008
US 2005038087 A1 20050217 US 2004-915001 20040810
PRIORITY APPLN. INFO.: FR 1999-12643 A 19991011

FR 2000-10151 A 20000801

FR 2000-11169 A 20000901

EP 2000-967988 A3 20001010

EP 2002-76763 A3 20001010

WO 2000-FR2805 W 20001010

FR 2001-4943 A 20010410

FR 2002-1811 A 20020214

US 2002-89993 A2 20020404

WO 2002-FR1218 A1 20020409

US 2003-681002 A2 20031008

OTHER SOURCE(S): MARPAT 134:311210
GI

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN



ACCESSION NUMBER: 2001:283789 CAPLUS
DOCUMENT NUMBER: 134:311210
TITLE: 5-Membered heterocycle derivatives useful as
monoamine oxidase inhibitors, lipid peroxidation inhibitors,
and sodium channel modulators, and the production
thereof,

INVENTOR(S): and use thereof as medicaments
Chabrier de Lassauliere, Pierre-Etienne; Harnett, Jeremiah; Bigg, Dennis; Pommier, Jacques; Lannoy, Jacques; Liberatore, Anne-Marie; Thureau, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S., Fr.
SOURCE: PCT Int. Appl., 261 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GM, GW, ML, MR, NE, SH, TD, TG				
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
CA 2388505	AA	20010419	CA 2000-2388505	20001010
BR 2000014649	A	20020618	BR 2000-14649	20001010
EP 1223933	A2	20020724	EP 2000-967988	20001010
EP 1223933	B1	20060906		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511416	T2	20030325	JP 2001-529718	20001010


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-Q [I, wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S; n = 0-6; R1, R2 = especially H, alkyl, or cycloalkyl; Q = NR3R4 or OR5; R3 and R4 = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, or aralkoxyalkyl or (cycloalkyl)alkoxyalkyl; R5 = H, alkyl, alkynyl, or cyanoalkyl]. I and their racemates, enantiomers, and/or salts can be used

for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P285)2 in 63% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and salification (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex preps., and

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 inhibited specific binding of [³H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.
 IT 335246-82-7P, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 MAO 335246-82-7 CAPLUS
 RN 335246-82-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




IT 252279-09-7, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-59-8, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptanamine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 MAO 252279-09-7 CAPLUS
 RN 252279-09-7 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α R)- (9CI) (CA INDEX NAME)



RN 335246-59-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-93-4P, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-95-6P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine hydrochloride 335245-17-5P, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335245-72-2P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335245-88-0P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine hydrochloride 335246-39-4P, 1-Methyl-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-49-6P, (1R)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine 335246-57-6P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-2-cyclohexylethanamine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 MAO 335243-08-8 CAPLUS
 RN 335243-08-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, α , α -dimethyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-12-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, hydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335243-21-5 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl-, hydrochloride (9CI)


09/26/2006

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




IT 335243-08-8P, 1-Methyl-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-12-4P, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335243-21-5P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine hydrochloride 335243-25-9P, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335243-44-2P, (R,S)-2-(1H-indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-45-3P, (1R)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-2-(1H-indol-3-yl)ethanamine hydrochloride 335243-46-4P, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-47-5P, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-51-1P, (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-60-2P, (1R)-2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335243-72-6P, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-81-7P, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine hydrochloride 335243-82-8P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-92-0P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine hydrochloride 335244-11-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-2-cyclohexylethanamine hydrochloride 335244-27-4P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-3-phenyl-1-propanamine hydrochloride 335244-36-5P, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pentanamine hydrochloride 335244-42-3P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)pentylamine hydrochloride 335244-45-6P, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-46-7P, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-49-0P, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-51-4P, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-52-5P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-59-1P, (1S)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-propanamine hydrochloride 335244-61-6P, (1S)-1-[4,5-Diphenyl-1H-imidazol-2-yl]-1-propanamine hydrochloride 335244-67-2P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile hydrochloride 335244-68-3P, (R,S)-1-[4-(4-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-71-8P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-butanamine hydrochloride 335244-72-9P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di-(tert-butyl)phenol hydrochloride 335244-73-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335244-80-9P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335244-81-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335244-82-1P, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-83-2P,

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 (CA INDEX NAME)




● x HCl

RN 335243-25-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-44-2 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335243-45-3 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4,5-diphenyl-1H-imidazol-2-yl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335243-46-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-47-5 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335243-51-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



● x HCl


RN 335243-82-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 335243-92-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335244-11-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(cyclohexylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335243-60-2 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 335243-72-6 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335243-81-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335244-27-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl


RN 335244-36-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-42-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-45-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-46-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-49-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●x HCl


RN 335244-61-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -ethyl-4,5-diphenyl-, hydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 335244-67-2 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-68-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




●x HCl

RN 335244-51-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-52-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-58-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335244-71-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 335244-72-9 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-73-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335244-80-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-81-0 CAPLUS
CN 1H-imidazole-2-methanamine, α-methyl-4-phenyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


RN 335244-82-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● x HCl


RN 335245-17-5 CAPLUS
CN 1H-imidazole-2-methanamine, 5-fluoro-α-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335245-72-2 CAPLUS
CN 1H-imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335245-88-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335244-83-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-93-4 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-95-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● x HCl

RN 335246-39-4 CAPLUS
CN 1H-imidazole-2-methanamine, α,α-dimethyl-4-phenyl-, (9CI) (CA INDEX NAME)




RN 335246-49-6 CAPLUS
CN 1H-imidazole-2-methanamine, α-(4,5-diphenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-57-6 CAPLUS
CN 1H-imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335247-08-0 CAPLUS


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-14-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(cyclohexylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 167983-80-4, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 252279-15-5, (1R)-2-(1H-Indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethanamine 335246-23-6, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol 335246-41-8, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine 335246-42-9, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-48-5, (R,S)-2-(1H-Indol-3-yl)-1-(5-methyl-4-phenyl-1H-imidazol-2-yl)ethanamine 335246-50-9, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-51-0 (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-23-6 CAPLUS
 CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 335246-41-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-42-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-48-5 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-methyl-5-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 335246-54-3, (R,S)-2-[6-Chloro-1H-indol-3-yl]-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-56-5, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine 335246-67-8, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-3-phenyl-1-propanamine 335246-69-0, (R,S)-1-(4-(4-Methylphenyl)-1H-imidazol-2-yl)-1-heptanamine 335246-70-3, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-71-4, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine 335246-72-5, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-73-6, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-74-7, (1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine 335246-75-8, (1S)-1-(4,5-Diphenyl-1H-imidazol-2-yl)-1-propanamine 335246-77-0, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile 335246-78-1, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine 335246-79-2, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine 335246-80-5, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline 335246-81-6, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine 335246-83-8, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-87-2, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-91-8, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)ethylamine
 RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified): THU (Therapeutic use): BIOL (Biological study):

USES
 (Uses)
 (drug candidate; prepn. of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 167983-80-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252279-15-5 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-50-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-51-0 CAPLUS
 CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS
 CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335246-56-5 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-67-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-([1,1'-biphenyl]-4-yl)-α-(2-phenylethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-69-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-([1,1'-biphenyl]-4-yl)-α-hexyl- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-([1,1'-biphenyl]-4-yl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)-α-hexyl- (9CI) (CA INDEX NAME)


L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl- (9CI) (CA INDEX NAME)



RN 335246-74-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-ethyl-4,5-diphenyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-75-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-ethyl-4,5-diphenyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 335246-81-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

L5 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 335247-34-2P, 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 335247-34-2 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- α -(4-methylpentyl)-(9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2001:101103 CAPLUS
 DOCUMENT NUMBER: 134:163050
 TITLE: Preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxopyrimidinone derivatives and their affinity for somatostatin receptors
 INVENTOR(S): Poitout, Lydie; Thuriereau, Christophe; Breult, Valerie
 PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S., Fr.
 SOURCE: PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009090	A2	20010208	WO 2000-FR2164	20000728
WO 2001009090	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2796945	A1	20010202	FR 1995-9886	19990730
FR 2796945	B1	20020628		
CA 2380070	AA	20010208	CA 2000-2380070	20000728
AU 2000070091	A5	20010219	AU 2000-70091	20000728
AU 779357	B2	20050120		
BR 2000012852	A	20020430	BR 2000-12852	20000728
EP 1246807	A2	20021009	EP 2000-958634	20000728
EP 1246807	B1	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NZ 516718	A	20030429	NZ 2000-516718	20000728
JP 2003518011	T2	20030603	JP 2000-514294	20000728
AT 308525	E	20051115	AT 2000-958634	20000728
ES 2252051	T3	20060516	ES 2000-958634	20000728
RU 2277093	C2	20060527	RU 2002-105024	20000728
US 6759415	B1	20040706	US 2002-48144	20020123
NO 2002000463	A	20020213	NO 2002-463	20020129
HK 1052510	A1	20050429	HK 2003-104848	20030708
US 2004209908	A1	20041021	US 2004-613139	20040330
PRIORITY APPLN. INFO.:			FR 1999-9886	A 19990730
			WO 2000-FR2164	W 20000728
			US 2002-48144	A3 20020123

L5 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:279029 CAPLUS
 DOCUMENT NUMBER: 135:107278
 TITLE: Novel non-peptide ligands for the somatostatin sst3 receptor
 AUTHOR(S): Moinet, C.; Contour-Galceras, M.-O.; Poitout, L.; Morgan, B.; Gordon, T.; Roubert, P.; Thuriereau, C.
 CORPORATE SOURCE: ZA de Courtaboeuf, Institut Henri Beaufour, Les Ulis, F-91966, Fr.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001) 1, 11(8), 991-995
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of imidazole derivs. has been prepared using high throughput parallel synthesis. Several compds. showed high affinity (Ki in 10⁻⁶-10⁻⁸ M range) and selectivity at recombinant human somatostatin receptor subtype 3 (hsst3).
 IT 252279-09-7P
 RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)
 RN 252279-09-7 CAPLUS
 CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (uR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

OTHER SOURCE(S): MARPAT 134:163050
 GI



AB The title compds. I [R1 = carbocyclic or heterocyclic aryl radical optionally substituted or a nonarom. heterocyclic radical optionally substituted; R2 = H, alkyl, aryl; R3 = H, (CH2)pZ3, Z3 = alkyl, cycloalkyl, bisarylalkyl, diarylalkyl, V1(CH2)p-phenyl-(X1)n, carbocyclic or heterocyclic aryl, nonarom. heterocyclic radical, X1 = H, Cl, F, Br, I, CF3, NO2, OH, NH2, CN, N3, OCF3, alkyl, alkoxy, S-alkyl, (CH2)pNH2, (CH2)pNH-alkyl, (CH2)pN-dialkyl; Y1 = O, S, NH, -; R4 = (CH2)pZ4, Z4 = amino, alkylamino, N,N-dialkylamino; R5 = H, alkyl; X = O, S; p 0-6; q = 1-5; n = 0, 1; provided that when n represents 0, m represents 1, 2 or 3, and when n represents 1, m represents 0 or 1], useful for treating pathol. conditions or diseases wherein somatostatin receptors are involved, were prepared E.g., benzyl (2S)-2-amino-3-(4-phenyl-1H-imidazol-2-yl)propanoate was prepared
 IT 325139-12-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxopyrimidinone derivs. and their affinity for somatostatin receptors)
 RN 325139-12-6 CAPLUS
 CN 1H-Imidazole-2-propanoic acid, β -amino-4-phenyl-, phenylmethyl ester, dihydrochloride, (R3)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

L5 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L5 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:31491 CAPLUS
 DOCUMENT NUMBER: 134:100877
 TITLE: Preparation of N-imidazolylmethyl carboxamides as nitric oxide production inhibitors
 INVENTOR(S): Shima, Ichiro; Ohkawa, Takehiko; Ohne, Kazuhiko; Zenkoh, Tatsuya; Sato, Kentaro
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002387	A1	20010111	WO 2000-JP4302	20000629
<--				
W: JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1196407	A1	20020417	EP 2000-940882	20000629
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003503489	T2	20030128	JP 2001-507824	20000629
PRIORITY APPLN. INFO.:			AU 1999-1425	A 19990705
			WO 2000-JP4302	W 20000629


OTHER SOURCE(S): MARPAT 134:100877
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = benzofuranyl substituted by halo, styryl substituted by halo; R2 = H, alkyl; R3 = pyridyl, optionally protected OH or alkylsulfonylamino; R4 = alkyl; R5, R6 = H, alkyl; X = CH, N] and their pharmaceutically acceptable salts which possess a strong inhibitory activity on the production of nitric oxide (NO), and therefore are useful for prevention and/or treatment of NO-mediated diseases in human being and animals, were prepared E.g., a multi-step synthesis of (2E,1S)-II which showed 100% inhibition of NO production, was given.
 IT 319458-94-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-imidazolylmethyl carboxamides as nitric oxide production inhibitors)
 RN 319458-94-1 CAPLUS
 CN 1H-imidazole-2-methanamine, 1-methyl-5-[4-(4-morpholinyl)phenyl]-u-

L5 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [(phenylmethoxymethyl)-, trihydrochloride, (uR)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




● 3 HCl

IT 209528-21-2P 319458-76-9P 319458-80-5P
 319458-83-8P 319458-88-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-imidazolylmethyl carboxamides as nitric oxide production inhibitors)

RN 209528-21-2 CAPLUS
 CN 2-Pyridineethanamine, α-[5-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-1H-imidazol-2-yl]-, (uS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 319458-76-9 CAPLUS
 CN 2-Pyridineethanamine, α-[5-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-1H-imidazol-2-yl]-, (uS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 319458-80-5 CAPLUS
 CN 1H-imidazole-2-ethanol, β-amino-α,1-dimethyl-5-[4-(4-morpholinyl)phenyl]-, trihydrochloride, (uR,βR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 3 HCl

RN 319458-83-8 CAPLUS
 CN Carbamic acid, [(2S)-2-amino-2-[1-methyl-5-[4-(4-morpholinyl)phenyl]-1H-imidazol-2-ylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 319458-88-3 CAPLUS
 CN 1H-imidazole-2-ethanol, β-amino-1-methyl-5-[4-(4-morpholinyl)phenyl]-, (βR)-, triacetate (salt) (9CI) (CA INDEX NAME)

L5 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 319458-87-2
CMF C16 H22 N4 O2

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:314693 CAPLUS

DOCUMENT NUMBER: 132:321861

TITLE: Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles and their preparation, compositions, and use

INVENTOR(S): Revesz, Laszlo

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026209	A1	20000511	WO 1999-EP8358	19991102
<--				
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9964765	A1	20000522	AU 1999-64765	19991102
<--				
PRIORITY APPLN. INFO.:			GB 1998-24063	A 19981103
			GB 1999-3440	A 19990215
			WO 1999-EP8358	W 19991102

OTHER SOURCE(S): MARPAT 132:321861

GI



AB Novel 4-phenyl-5-[2-(Y-X)-4-pyrimidinyl]imidazoles [Y = aryl, cycloalkyl, aralkyl, or cycloalkylalkyl; X = N, O, S] and their pharmaceutically

L5 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

acceptable and cleavable esters and acid addn. salts are provided. In particular, compds. I and their esters and salts are disclosed [wherein

R1 = pyrimidinyl; X = NR6Y, O, S; R6 = H, alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; Y = alkylene or bond; R2 = (un)substituted Ph; R3 = H, heterocyclyl, heterocyclylalkyl, (un)substituted alk(en/yn)yl, cycloalkyl,

aryl, etc.; R4 = H, (un)substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R5 = (un)substituted aryl, heteroaryl, or cycloalkyl]. The compds. are MAP kinase inhibitors, useful pharmaceutically for treating TNF α and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metab., e.g., osteoporosis. Use of the compds. as antiinflammatory and immunosuppressant agents is specifically claimed. For example, 4-methyl-2-(methylthio)pyrimidine was lithiated with BuLi and C-acylated with 4-fluoro-N-methoxy-N-methylbenzamide to give 65% 4-fluoro-2'-[(2-methylthio-4-pyrimidinyl)acetophenone. The latter underwent α -bromination (100%), cyclization with formamide and ammonium formate to give an imidazole (38%), S-oxidn. with mCPBA to give the sulfoxide (70%), and substitution reaction with 3-fluoroaniline (18%) to give title compd. II. The compds. had typical IC50 values of 100 nM to 10 nM or less in a p38 MAP kinase inhibition assay, and gave up to approx. 50% inhibition of TNF prodn. in LPS-stimulated mice at 10 mg/kg orally.

IT 266358-00-3P, (R)-5-(4-Fluorophenyl)-2-(1-amino-1-methylethyl)-4-[2-(1-phenylethylamino)-4-pyrimidinyl]-1H-imidazole 266358-01-4P, (S)-5-(4-Fluorophenyl)-2-(1-amino-1-methylethyl)-4-[2-(1-phenylethylamino)-4-pyrimidinyl]-1H-imidazole 266358-02-5P, 5-(4-Fluorophenyl)-2-(1-amino-1-methylethyl)-4-(2-cyclohexylamino-4-pyrimidinyl)-1H-imidazole 266358-03-6P, 5-(4-Fluorophenyl)-2-(1-amino-1-methylethyl)-4-[2-(cyclopropylmethylamino)-4-pyrimidinyl]-1H-imidazole

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of phenylpyrimidinylimidazoles as antiinflammatories and immunosuppressants)

RN 266358-00-3 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(1-amino-1-methylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 266358-01-4 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(1-amino-1-methylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 266358-02-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-(1-amino-1-methylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-N-cyclohexyl- (9CI) (CA INDEX NAME)

L5 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 266358-03-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2-(1-amino-1-methylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Imidazole-containing somatostatin cyclic derivs. I [Y, Z = D- or L-natural or unnatural α -amino acid; n = 0-50, provided that both n cannot be zero at the same time; m = 1-10; a = H or R1; b = OH, OR1, or (un)substituted amino or a and b form an amide bond; R1 = H, alkyl, arylalkyl; R2 = H or (un)substituted alkyl, Ph, phenylalkyl, or heterocyclalkyl; R3, R4 = H or (un)substituted alkyl, cycloalkyl, aryl, or arylalkyl or R3 and R4 together with carbons to which they are attached are (un)substituted aryl; R5 = H or (un)substituted alkyl or arylalkyl;
R6 = H, alkyl, alkoxy, arylalkyl, or arylalkoxy] were prepared which selectively bind to somatostatin receptor subtypes. Thus, cyclo[Tyr-D-Trp-Lys-Val-PheV[4-(3-methoxyphenyl)imidazole]-Gly] was prepared by a multistep procedure starting with cyclocondensation of benzoyloxycarbonyl-L-phenylalanine with 2-bromo-3'-methoxyacetophenone to form 2-[1-(S)-amino-2-phenylethyl]-4-(3-methoxyphenyl)imidazole, followed by protection, peptide coupling, and deprotection steps.
IT 252753-48-3P
R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic somatostatin analogs)
RN 252753-48-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-methoxyphenyl)- α -(phenylmethyl)-, (α S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:811276 CAPLUS
DOCUMENT NUMBER: 132:50255
TITLE: Preparation of cyclic somatostatin analogs
INVENTOR(S): Gordon, Thomas D.
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Fr.
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965942	A1	19991223	WO 1999-US13304	19990611
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335184	AA	19991223	CA 1999-2335184	19990611
AU 9948223	A1	20000105	AU 1999-48223	19990611
AU 745493	B2	20020321		
EP 1086131	A1	20010328	EP 1999-931793	19990611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002518409	T2	20020625	JP 2000-554767	19990611
RU 2242481	C2	20041220	RU 2001-101530	19990611
TW 527361	B	20030411	TW 1999-88110016	19990615
NO 2000006320	A	20010212	NO 2000-6320	20001212
US 6602849	B1	20030805	US 2001-719784	20010214
PRIORITY APPLN. INFO.:			US 1998-89503P	P 19980616
			US 1998-98181	A1 19980616
			WO 1999-US13304	W 19890611
OTHER SOURCE(S):		MARPAT 132:50255		
GI				

L5 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:795813 CAPLUS
DOCUMENT NUMBER: 132:35702
TITLE: Preparation of imidazolyl- β -carbolines and related compounds as somatostatin receptor mediators and sodium channel blockers.
INVENTOR(S): Thirieau, Christophe Alain; Poitout, Lydie Francine; Gálcerá, Marie-odile; Moinet, Christophe Philippe; Gordon, Thomas D.; Morgan, Barry A.; Bigg, Dennis C. H.; Pommier, Jacques
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques S. A., Fr.
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964420	A1	19991216	WO 1999-US12874	19990608
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335339	AA	19991216	CA 1999-2335339	19990608
AU 9945536	A1	19991230	AU 1999-45536	19990608
AU 761020	B2	20030529		
EP 1086101	A1	20010328	EP 1999-928479	19990608
EP 1086101	B1	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002517500	T2	20020618	JP 2000-553429	19990608
AT 229954	E	20030115	AT 1999-928479	19990608
ES 2188184	T3	20030616	ES 1999-928479	19990608
NZ 508765	A	20031031	NZ 1999-508765	19990608
RU 2233841	C2	20040810	RU 2001-101433	19990608
TW 236477	B1	20050721	TW 1999-88109827	19990811
NO 2000006268	A	20010129	NO 2000-6268	20001211
NO 319532	B1	20050829		
HK 1032049	A1	20030417	HK 2001-102432	20010404
US 6586445	B1	20030701	US 2001-719455	20010613
US 2004038970	A1	20040226	US 2003-383949	20030307
PRIORITY APPLN. INFO.:			US 1998-89180P	P 19980612
			US 1998-97297	A1 19980612
			WO 1999-US12874	W 19990608

L5 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2001-719455 A3 20010613

OTHER SOURCE(S): MARPAT 132:35702
GI



AB Title compds. [I: dotted lines = optional double bonds; X = N, NR4; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, (CH2)mOZ1, etc.; Z1 = (substituted) alkyl, benzothienyl, Ph, naphthyl, benzofuryl, thienyl, indolyl, etc.; R2 = alkyl, ACOZ25, (substituted) Ph, etc.; Z5 = H, alkyl, aryl, aralkyl; R3 = H; R4 = CYNX1X2, COX2, X2; Y = O, S; X2 = (CH2)mY1X3; X3 = H, (substituted) alkyl, cycloalkyl, alkoxy, aryloxy, alkylamino, Ph, etc.;


Y1 = O, S, NH, bond; R5 = alkyl, cycloalkyl, (substituted) Ph, furyl, thienyl, pyrrolyl, pyridinyl, etc.; R6 = H, PhSO2; R7 = H, alkyl, alkoxyalkyl, dialkylaminoalkyl; X1 = H, Cl, F, Br, Iodo, NO2, OH, CF3, alkyl, etc.; m = 0-6; n = 1-5, were prepared as drugs (no data). Thus, 2-[1(S)-amino-2-(3-indolyl)ethyl]-4-phenyl-1H-imidazole in CHCl3 was treated with p-anisaldehyde and CF3CO2H followed by 2 days stirring to give a residue which was stirred overnight with aminomethylpolystyrene resin in THF to give 78% 1,2,3,4-tetrahydro-1(RS)-(4-methoxyphenyl)-3(S)-(4-phenyl-1H-imidazol-2-yl)-9H-pyrido[3,4-b]indole.

IT 252279-08-6 252279-09-7 252279-12-2
252279-13-3 252279-14-4 252279-15-5
252279-34-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl-β-carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)

RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 252279-14-4 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-15-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-34-8 CAPLUS
CN 1H-Indazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252279-23-5P
09/26/2006

L5 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-12-2 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-13-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of imidazolyl-β-carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)
RN 252279-23-5 CAPLUS
CN 1H-Indazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:795794 CAPLUS
DOCUMENT NUMBER: 132:35701
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors
INVENTOR(S): Thuriereau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moinet, Christophe Philippe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques, S.A., Fr.
SOURCE: PCT Int. Appl., 342 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964401	A2	19991216	WO 1999-US12760	19990608
WO 9964401	A3	20030417		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RU: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2334945	AA	19991216	CA 1999-2334945	19990608
AU 9944257	A1	19991230	AU 1999-44257	19990608
AU 746963	B2	20020509		
EP 1086086	A1	20010328	EP 1999-927323	19990608
EP 1086086	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003523921	T2	20030812	JP 2000-553410	19990608
AT 279396	E	20041015	AT 1999-927323	19990608
PT 1086086	T	20050228	PT 1999-927323	19990608
ES 2229718	T3	20050416	ES 1999-927323	19990608
RU 2263111	C2	20051027	RU 2001-101429	19990608
IL 139835	A1	20051120	IL 1999-139835	19990608
NO 200006267	A	20010207	NO 2000-6267	20001211
HK 1031873	A1	20050304	HK 2001-102404	20010403
US 6852725	B1	20050208	US 2001-719457	20010613
US 2004176379	A1	20040909	US 2004-771725	20040204
NO 2006000154	A	19991213	NO 2006-154	20060110
PRIORITY APPLN. INFO.:			US 1998-89087P	P 19980612


L5 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L5 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 1998-96431 A1 19990612
WO 1999-US12760 W 19990608
US 2001-719457 A3 20010613
OTHER SOURCE(S): MARPAT 132:35701
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I: R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mAl; Al = C(:Y)NK1X2; C(:Y)X2; C(:NH)X2, X2: Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.; m = 0-6] which are useful as agonists or antagonists of somatostatin receptors (no data), and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addition of 2-((1S)-1-amino-2-(indol-3-yl)ethyl)-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day. 252279-08-6 252279-09-7
IT R1: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (nS)-(9CI) (CA INDEX NAME)
Absolute stereochemistry.



RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (nR)-(9CI) (CA INDEX NAME)
Absolute stereochemistry.

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:723031 CAPLUS
DOCUMENT NUMBER: 131:337023
TITLE: Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production
INVENTOR(S): Shima, Ichiro; Ohkawa, Takehiko; Ohne, Kazuhiko; Zenko, Tatsuya; Oku, Teruo; Yoshihara, Kousui; Setoi, Hiroyuki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 88 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957114	A1	19991111	WO 1999-JP2231	19990426
W: JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1075475	A1	20010214	EP 1999-917174	19990426
EP 1075475	B1	20030618		
R: CH, DE, ES, FR, GB, IT, LI JP 2002511889	T2	20020416	JP 1999-553958	19990426
ES 2196798	T3	20031216	ES 1999-917174	19990426
US 2002132809	A1	20020919	US 2002-80663	20020225
PRIORITY APPLN. INFO.:			AU 1998-3324	A 19980504
			AU 1998-4014	A 19980610
			WO 1999-JP2231	W 19990426
			US 2000-673660	A1 20001220

OTHER SOURCE(S): MARPAT 131:337023
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. (I) [wherein R1 = indolyl, NO2 or halogen substituted benzothienyl, (nitro)furofurydyl, or benzofuranly optionally substituted with halogen, (trihalo)alkyl, alkoxy, NO2, cyano, or acyl; R2 = alkyl; R3 = H or alkyl; R4 = thienyl or Ph substituted with halogen, imidazolyl, benzimidazolyl, pyridyl, pyrrolyl, morpholinyl, thienyl, furyl, Ph, thiazolyl, or NO2] were prepared for use in the treatment and/or prevention of NO-mediated diseases. For example, condensation of the 1-imidazolyl-2-pyridylethylamine (II) (seven step preparation given) with 5-chlorobenzo[b]furan-2-carboxylic acid in DMF yielded the benzo[b]furan-2-ylcarboxamide (III). III and six other test compds. inhibited nitric oxide production by 100% in murine macrophage cell line

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RAW264.7 at 10-5 M. The combination of III (10 mg/kg) and the immunosuppressive agent FK506 (0.32 mg/kg) prolonged the median survival time from 10 to >30 days for cardiac allografts in male Lewis and ACI rats.

IT 209526-60-3P 209527-29-7P 209528-15-4P
 209528-21-2P 209528-25-6P 209528-98-3P
 209529-05-5P 249639-71-2P 249639-73-4P
 249639-75-6P 249639-77-8P 249639-84-7P
 249639-92-7P 249640-08-2P 249640-14-0P
 249640-20-8P 249640-26-4P 249640-33-3P
 249640-35-5P 249640-37-7P 249640-42-4P
 249640-44-6P 249642-01-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of heterocyclic carboxamide derivs. as inhibitors of nitric oxide prodn for treatment of NO-mediated diseases, particularly for use as immunosuppressant agents in transplantation)


RN 209526-60-3 CAPLUS
 CN 2-Pyridineethanamine, α -[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-29-7 CAPLUS
 CN 2-Pyridineethanamine, α -[5-(4-bromophenyl)-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-15-4 CAPLUS
 CN 2-Pyridineethanamine, α -[1-ethyl-5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 4 HCl


RN 209529-05-5 CAPLUS
 CN 2-Pyridineethanamine, α -[5-(1,1'-biphenyl)-4-yl-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249639-71-2 CAPLUS
 CN 2-Pyridineethanamine, α -[1-methyl-5-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249639-73-4 CAPLUS
 CN 2-Pyridineethanamine, α -[5-[4-(2-furanyl)phenyl]-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209528-21-2 CAPLUS
 CN 2-Pyridineethanamine, α -[1-methyl-5-[4-(4-morpholinyl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-25-6 CAPLUS
 CN 2-Pyridineethanamine, α -[5-[4-(1H-imidazol-1-yl)phenyl]-1-propyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-98-3 CAPLUS
 CN 2-Pyridineethanamine, α -[5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazol-2-yl]-, tetrahydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 249639-75-6 CAPLUS
 CN 2-Pyridineethanamine, α -[1-methyl-5-[4-(2-thienyl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249639-77-8 CAPLUS
 CN 2-Pyridineethanamine, α -[1-methyl-5-[4-(2-thiazolyl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249639-84-7 CAPLUS
 CN 2-Pyridineethanamine, α -[5-[3-fluoro-4-(4-morpholinyl)phenyl]-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 249639-92-7 CAPLUS
 CN 2-Pyridineethanamine, α-[5-(2,4-dichlorophenyl)-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249640-08-2 CAPLUS
 CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(1-methyl-1H-imidazol-2-yl)phenyl]-1H-imidazol-2-yl]-, tetrahydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 4 HCl

RN 249640-14-0 CAPLUS
 CN 2-Pyridineethanamine, α-[5-[4-(1H-imidazol-1-yl)phenyl]-1,4-dimethyl-1H-imidazol-2-yl]-, tetrahydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 249640-35-5 CAPLUS
 CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(2-pyridinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249640-37-7 CAPLUS
 CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(4-pyridinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 249640-42-4 CAPLUS
 CN 4-Pyridineethanamine, α-[5-[4-(1H-imidazol-1-yl)phenyl]-1-propyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 4 HCl


RN 249640-20-8 CAPLUS
 CN 2-Pyridineethanamine, α-[5-[4-(1H-benzimidazol-1-yl)phenyl]-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 249640-26-4 CAPLUS
 CN 2-Pyridineethanamine, α-[5-[4-(2-ethyl-1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 249640-33-3 CAPLUS
 CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(3-pyridinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

L5 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 249640-44-6 CAPLUS
 CN 4-Pyridineethanamine, α-[1-ethyl-5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 249642-01-1 CAPLUS
 CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(5-thiazolyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1999:659221 CAPLUS
 DOCUMENT NUMBER: 131:281563
 TITLE: Use of nitric oxide inhibitors to enhance the effect of IL-2 inhibitors
 INVENTOR(S): Sakai, Fumihiko; Yamazaki, Harumi; Chida, Noboru; Nakayama, Osamu; Yokota, Yoshihiro
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951215	A2	19991014	WO 1999-JP1806	19990405
<--				
WO 9951215	A3	20000309		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9930563	A1	19991025	AU 1999-30563	19990405
<--				
EP 1067926	A2	20010117	EP 1999-912114	19990405
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002509555	T2	20020326	JP 1999-550302	19990405
<--				
US 6673807	B1	20040106	US 2000-646886	20001201
US 2004092436	A1	20040513	US 2003-702427	20031107
PRIORITY APPLN. INFO.:				
			AU 1998-2827	A 19980406
			AU 1998-3324	A 19980504
			AU 1998-5056	A 19980804
			WO 1999-JP1806	W 19990405
			US 2000-646886	A3 20001201

GI

L5 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB Compds. possessing an inhibitory activity on the production of nitric oxide are used for increasing the effect caused by IL-2 inhibitor, such as tacrolimus. Thus, the amine fragment of the amide I was prepared from 2-amino-4'-morpholinoacetophenone and (2S)-tert.-butoxycarbonylamino-3-(2-pyridyl)propanoic acid in 3 steps and was acylated with 5-chloro-2-benzofurancarboxylic acid to give I. At 1X10⁻⁵ M I gave 100% inhibition of NO generation in murine macrophage RAW264.7 cells. I also enhanced the immunosuppressant effect of FK506 in rat allograft.

IT 209528-25-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of imidazolepropanoamides for use as nitric oxide inhibitors to enhance the effect of IL-2 inhibitors)

RN 209528-25-6 CAPLUS
 CN 2-Pyridineethanamine, α-[5-[4-(1H-imidazol-1-yl)phenyl]-1-propyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

IT 209525-91-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of imidazolepropanoamides for use as nitric oxide inhibitors to enhance the effect of IL-2 inhibitors)

RN 209525-91-7 CAPLUS
 CN 2-Pyridineethanamine, α-[5-(4-ethoxyphenyl)-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 209528-21-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazolepropanoamides for use as nitric oxide inhibitors to enhance the effect of IL-2 inhibitors)

RN 209528-21-2 CAPLUS
 CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(4-morpholinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 200070-05-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of imidazolepropanoamides for use as nitric oxide inhibitors to enhance the effect of IL-2 inhibitors)

RN 200070-05-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, α-[(4-methoxyphenyl)methyl]-1-methyl-5-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:424263 CAPLUS
 DOCUMENT NUMBER: 129:95714
 TITLE: Preparation of new heterocyclic amides as nitric oxide
 oxide
 INVENTOR(S): production inhibitors
 Yatabe, Takumi; Inoue, Takayuki; Hamashima, Hitoshi;
 Shima, Ichiro; Ohne, Kazuhiko; Yoshihara, Kousei;
 Oku, Teruo
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Itoh,
 Yoshikuni
 SOURCE: PCT Int. Appl., 533 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827108	A2	19980625	WO 1997-JP4243	19971120
WO 9827108	A3	19980730		
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749680	A1	19980715	AU 1997-49680	19971120
EP 946587	A2	19991006	EP 1997-912529	19971120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001505585	T2	20010424	JP 1998-527528	19971120
ZA 9710603	A	19980625	ZA 1997-10603	19971125
PRIORITY APPLN. INFO.:				
		AU 1996-4219	A	19961216
		AU 1997-5929	A	19970401
		AU 1997-9030	A	19970909
		WO 1997-JP4243	W	19971120


OTHER SOURCE(S): MARPAT 129:95714
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = S, NR9; Y = CHR3], (un)substituted phenylene; R1 = (un)substituted indolyl, (un)substituted benzofuranlyl; R2 = H,

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 209526-06-7P 209526-09-0P 209526-12-5P
 209526-15-8P 209526-18-1P 209526-21-6P
 209526-24-9P 209526-25-0P 209526-27-2P
 209526-29-4P 209526-42-1P 209526-45-4P
 209526-48-7P 209526-57-8P 209526-60-3P
 209526-63-6P 209526-72-7P 209526-74-9P
 209526-79-4P 209526-82-5P 209526-84-1P
 209526-87-4P 209526-90-9P 209526-97-6P
 209527-04-8P 209527-09-3P 209527-12-8P
 209527-15-1P 209527-18-4P 209527-21-9P
 209527-23-1P 209527-26-4P 209527-29-7P
 209527-35-5P 209527-37-7P 209527-43-5P
 209527-45-7P 209527-48-0P 209527-52-6P
 209527-55-9P 209527-57-1P 209527-63-9P
 209527-66-2P 209527-69-5P 209527-75-3P
 209527-78-6P 209527-81-1P 209527-84-4P
 209527-89-9P 209527-94-6P 209527-98-0P
 209528-01-8P 209528-04-1P 209528-08-5P
 209528-11-0P 209528-13-2P 209528-15-4P
 209528-18-7P 209528-21-2P 209528-23-4P
 209528-25-6P 209528-31-4P 209528-33-6P
 209528-36-9P 209528-39-2P 209528-42-7P
 209528-48-3P 209528-51-8P 209528-56-3P
 209528-94-9P 209528-97-2P 209528-98-3P
 209529-02-2P 209529-05-5P 209529-08-8P
 209529-10-2P 209529-12-4P 209529-14-6P
 209529-16-8P 209529-18-0P 209529-21-5P
 209529-25-9P 209529-29-3P 209529-35-1P
 209529-37-3P 209529-41-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of new heterocyclic amides as nitric oxide prodn. inhibitors)
 RN 200070-05-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -[(4-methoxyphenyl)methyl]-1-methyl-5-phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-08-2 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 phenyl-lower alkyl; R3 = H, (CH2)nR6; R4 = H, (un)substituted Ph, (un)substituted pyridyl; R5 = H, imidazolyl, Ph, nitrophenyl, phenyl-lower alkyl, optionally esterified carboxy, CONR7R8; R4R5 = CH:CHCH:CH; R6 = optionally protected OH, acyl, carboxy, acylamino, lower alkoxy, phenyl-lower alkoxy, lower alkylthio, (un)substituted Ph; R7, R8 = independently H, Ph, phenyl-lower alkyl, lower alkyl, lower alkoxy; R9 = H, lower alkyl, lower cycloalkyl, (un)substituted benzyl; m = 0, 1; n = 0-3] and pharmaceutically acceptable salts thereof are described as strong inhibitors of the prodn. of nitric oxide. Compds. I are useful for prevention and treatment of nitric oxide-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock, diabetes, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease, cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, post-herpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancreatitis, atherosclerosis, and the like in humans and animals. Thus, 2-step cyclocondensation of amino ketone II (prepn. given) with protected 3-(2-pyridyl)-L-alanine and methylamine gave protected imidazole III (Boc = Me3CO2C). Deprotection of III followed by acylation with indole-2-carboxylic acid gave desired compd. IV. IV inhibited nitric oxide prodn. 100% in murine macrophage cell line RAW264.7 at 10⁻⁵ M.
 IT 209529-42-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of new heterocyclic amides as nitric oxide production inhibitors)
 RN 209529-42-0 CAPLUS
 CN 2-Pyridineethanamine, α -[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 200070-05-9P 200070-08-2P 200070-17-3P
 200070-20-8P 200070-57-1P 209525-91-7P
 209525-94-0P 209525-97-3P 209526-03-4P

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 200070-17-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)-1-methyl- α -(phenylmethyl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-20-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-chlorophenyl)-1-methyl- α -(phenylmethyl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-57-1 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-ethoxyphenyl)-1-methyl- α -(phenylmethyl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209525-91-7 CAPLUS
 CN 2-Pyridineethanamine, α -[5-(4-ethoxyphenyl)-1-methyl-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 209525-94-0 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209525-97-3 CAPLUS
CN 4-Pyridineethanamine, α-[5-(4-ethoxyphenyl)-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-03-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(3,4-dichlorophenyl)-α-[(4-methoxyphenyl)methyl]-1-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209526-18-1 CAPLUS
CN 3-Pyridineethanamine, α-[5-(4-ethoxyphenyl)-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-21-6 CAPLUS
CN 4-Pyridineethanamine, α-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209526-24-9 CAPLUS
CN 1H-Indazole-3-carboxamide, 2-[(1S)-1-amino-2-phenylethyl]-5-(4-bromophenyl)-N,N,1-trimethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-25-0 CAPLUS

09/26/2006

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 209526-06-7 CAPLUS
CN Benzonitrile, 4-[2-[(1S)-1-amino-2-phenylethyl]-1-methyl-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-09-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-[(4-methoxyphenyl)methyl]-1-methyl-5-[4-(trifluoromethyl)phenyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209526-12-5 CAPLUS
CN Benzonitrile, 4-[2-[(1S)-1-amino-2-(4-methoxyphenyl)ethyl]-1-methyl-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209526-15-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)-1-methyl-α-(2-naphthalenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 1H-Imidazole-4-carboxamide, 2-[(1S)-1-amino-2-phenylethyl]-5-(4-bromophenyl)-N-methoxy-N,1-dimethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-27-2 CAPLUS
CN 1H-Imidazole-4-carboxamide, 2-[(1S)-1-amino-2-phenylethyl]-5-(4-bromophenyl)-N,N,1-trimethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209526-29-4 CAPLUS
CN 1H-Indazole-3-carboxamide, 2-[(1S)-1-amino-2-phenylethyl]-5-(4-bromophenyl)-1-methyl-N-phenyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209526-42-1 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-α-(1-methyl-5-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209526-45-4 CAPLUS
CN 1H-imidazole-2-methanamine, 5-(4-bromophenyl)-1-methyl-α-[(4-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209526-48-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-[(4-methoxyphenyl)methyl]-1-methyl-5-(4-nitrophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-57-8 CAPLUS
CN 1H-imidazole-2-methanamine, 1-methyl-5-(4-nitrophenyl)-α-[(4-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 209526-74-9 CAPLUS
CN 2-Pyridineethanamine, α-[1-ethyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-79-4 CAPLUS
CN 2-Pyridineethanamine, α-[5-(4-(1H-imidazol-1-yl)phenyl)-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209526-82-9 CAPLUS
CN 4-Pyridineethanamine, α-[1-methyl-5-(4-(methylthio)phenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209526-84-1 CAPLUS
CN 4-Pyridineethanamine, α-[1-methyl-5-(4-(methylsulfonyl)phenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209526-60-3 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-63-6 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-72-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-(1,3-benzodioxol-5-ylmethyl)-5-(4-ethoxyphenyl)-1-methyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209526-87-4 CAPLUS
CN 2-Pyridineethanamine, α-[5-(4-(dimethylamino)phenyl)-1-methyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-90-9 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-(3-nitrophenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209526-97-6 CAPLUS
CN 2-Pyridineethanamine, 5-methoxy-α-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 209527-04-8 CAPLUS
CN 2-Pyridineethanamine, 5-chloro-α-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209527-09-3 CAPLUS
CN Pyrazineethanamine, α -([1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl])-(9CI) (CA INDEX NAME)




RN 209527-12-8 CAPLUS
CN 1H-imidazole-2-butanamine, γ -amino-1-methyl-5-(4-nitrophenyl)-phenylmethyl ester, (9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-15-1 CAPLUS
CN Acetamide, N-([4S]-4-amino-4-([1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]butyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209527-29-7 CAPLUS
CN 2-Pyridineethanamine, α -([5-(4-bromophenyl)-1-methyl-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-35-5 CAPLUS
CN 2-Pyridineethanamine, α -([5-(4-ethoxyphenyl)-1-methyl-4-phenylmethyl]-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-37-7 CAPLUS
CN 2-Pyridineethanamine, α -([5-(4-nitrophenyl)-1-propyl]-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-43-5 CAPLUS
CN 2-Pyridineethanamine, α -([1-methyl-5-(4-([1H-pyrazol-1-yl]phenyl)-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)

09/26/2006

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 209527-18-4 CAPLUS
CN 1H-imidazole-2-propanamide, β -amino-5-(4-ethoxyphenyl)-1-methyl-N-phenyl-, (9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-21-9 CAPLUS
CN 1H-imidazole-2-methanamine, α -([2-furanylmethyl]-1-methyl-5-(4-nitrophenyl)-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-23-1 CAPLUS
CN 2-Pyridineethanamine, α -([5-(4-nitrophenyl)-1-(phenylmethyl)-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-26-4 CAPLUS
CN 1H-imidazole-2-methanamine, α -([1,3-benzodioxol-5-ylmethyl]-1-methyl-5-(4-nitrophenyl)-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 209527-45-7 CAPLUS
CN 2-Pyridineethanamine, α -([1-ethyl-5-(4-([1H-pyrazol-1-yl]phenyl)-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-48-0 CAPLUS
CN 2-Pyridineethanamine, α -([1-methyl-5-(4-(methylthio)phenyl)-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209527-52-6 CAPLUS
CN 2-Pyridineethanamine, α -([5-(4-(2-methoxyethoxy)phenyl)-1-methyl-1H-imidazol-2-yl]-(9S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209527-55-9 CAPLUS
CN 1H-imidazole-2-propanoic acid, β -amino-1-methyl-5-(4-nitrophenyl)-, phenylmethyl ester, (RS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-57-1 CAPLUS
CN 1H-imidazole-2-propanamide, β -amino-N,1-dimethyl-5-(4-nitrophenyl)-, (RS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-63-9 CAPLUS
CN 3-pyridineethanamine, α -[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209527-81-1 CAPLUS
CN 2-pyridineethanamine, α -[5-(3-ethoxyphenyl)-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-84-4 CAPLUS
CN 1H-imidazole-2-ethanol, β -amino-1-methyl-5-(4-nitrophenyl)-, (HR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-89-9 CAPLUS
CN 1H-imidazole-2-ethanol, β -amino-1-methyl-5-(4-nitrophenyl)-, (HR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-94-6 CAPLUS
CN 2-pyridineethanamine, α -[5-(1,3-benzodioxol-5-yl)-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/26/2006

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 209527-66-2 CAPLUS
CN Benzoic acid, 4-[2-[(1S)-1-amino-2-(4-pyridinylethyl)-1-methyl-1H-imidazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-69-5 CAPLUS
CN Benzoic acid, 4-[2-[(1S)-1-amino-2-(2-pyridinylethyl)-1-methyl-1H-imidazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-75-3 CAPLUS
CN Benzonitrile, 4-[2-[(1S)-1-amino-2-(2-pyridinylethyl)-1-methyl-1H-imidazol-5-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209527-78-6 CAPLUS
CN 4-pyrimidineethanamine, α -[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209527-98-0 CAPLUS
CN 1H-imidazole-2-methanamine, α -(methoxymethyl)-1-methyl-5-(4-nitrophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209528-01-8 CAPLUS
CN 1H-imidazole-2-methanamine, 1-methyl-5-(4-nitrophenyl)- α -(phenylmethoxymethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209528-04-1 CAPLUS
CN 1H-imidazole-2-methanamine, α -[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209528-08-5 CAPLUS
CN 2-pyridineethanamine, α -[5-(4-chlorophenyl)-1-methyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 209528-11-0 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-(6-quinolinyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-13-2 CAPLUS
CN 1H-imidazole-2-propanoic acid, β-amino-1-ethyl-5-(4-nitrophenyl)-, phenylmethyl ester, (RS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-15-4 CAPLUS
CN 2-Pyridineethanamine, α-[1-ethyl-5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209528-25-6 CAPLUS
CN 2-Pyridineethanamine, α-[5-(4-(1H-imidazol-1-yl)phenyl)-1-propyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-31-4 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-33-6 CAPLUS
CN 2-Pyridineethanamine, α-[1-ethyl-5-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209528-18-7 CAPLUS
CN 2-Pyridineethanamine, α-[5-(4-ethoxyphenyl)-1-ethyl-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-21-2 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(4-morpholinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-23-4 CAPLUS
CN 2-Pyridineethanamine, α-[1-ethyl-5-[4-(4-morpholinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209528-36-9 CAPLUS
CN 2-Pyridineethanamine, α-[1-methyl-5-[4-(1-piperidinyl)phenyl]-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-39-2 CAPLUS
CN [2,4'-Bi-1H-imidazole]-2'-methanamine, 5'-(4-bromophenyl)-1'-methyl-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-42-7 CAPLUS
CN 2-Pyridineethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, trihydrobromide, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●3 HBr


RN 209528-48-3 CAPLUS
CN 1H-imidazole-4-carboxylic acid, 2-[(1S)-1-amino-3-oxo-3-(phenylamino)propyl]-1-methyl-5-(4-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209528-51-8 CAPLUS
CN 1H-imidazole-2-ethanamine, alpha-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, trihydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-56-3 CAPLUS
CN 1H-imidazole-2-ethanamine, alpha-[1-methyl-5-(4-nitrophenyl)-1H-imidazol-2-yl]-, trihydrochloride, (aS)- (9CI) (CA INDEX NAME)


L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●4 HCl


RN 209529-02-2 CAPLUS
CN 1H-imidazole-2-propanamide, beta-amino-N-1,3-benzodioxol-5-yl-5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209529-05-5 CAPLUS
CN 2-Pyridineethanamine, alpha-[5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209529-08-8 CAPLUS
CN 1H-imidazole-2-propanamide, beta-amino-5-[4-(1H-imidazol-1-yl)phenyl]-N-(4-methoxyphenyl)-1-methyl-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



●3 HCl


RN 209528-94-9 CAPLUS
CN 1H-imidazole-2-methanamine, 1-methyl-4,5-diphenyl-alpha-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-97-2 CAPLUS
CN 2-Pyridineethanamine, alpha-[1-methyl-5-[4-(4-methyl-1-piperazinyl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-98-3 CAPLUS
CN 2-Pyridineethanamine, alpha-[5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazol-2-yl]-, tetrahydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209529-10-2 CAPLUS
CN 2-Pyridineethanamine, alpha-[5-[4-(1H-imidazol-1-yl)phenyl]-1-(1-methylethyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209529-12-4 CAPLUS
CN 2-Pyridineethanamine, alpha-[1-butyl-5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209529-14-6 CAPLUS
CN 2-Pyridineethanamine, alpha-[5-[4-(1H-imidazol-1-yl)phenyl]-1-pentyl-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209529-16-8 CAPLUS
CN 2-Pyridineethanamine, α -[1-cyclopropyl-5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209529-18-0 CAPLUS
CN 2-Pyridineethanamine, α -[1-cyclobutyl-5-[4-(1H-imidazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (uS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209529-21-5 CAPLUS
CN 2-Pyridineethanamine, α -[5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazol-2-yl]-, (uR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209529-37-3 CAPLUS
CN 2-Pyridineethanamine, α -[1-propyl-5-[4-(1H-1,2,4-triazol-1-yl)phenyl]-1H-imidazol-2-yl]-, (uS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 209529-41-9 CAPLUS
CN 2-Pyridineethanamine, α -[5-[4-(1H-imidazol-1-yl)phenyl]-1-propyl-1H-imidazol-2-yl]-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

L5 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209529-25-9 CAPLUS
CN 4-Pyridineethanamine, α -[5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl-1H-imidazol-2-yl]-, (uS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209529-29-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl- α -[(phenylmethoxy)methyl]-, (uR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209529-35-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl- α -[(phenylthio)ethyl]-, (uS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:805737 CAPLUS
DOCUMENT NUMBER: 128:48225
TITLE: Preparation of new indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
INVENTOR(S): Itoh, Yoshikuni; Yatabe, Takumi; Inoue, Takayuki; Hamashima, Hiroshi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIKXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745425	A1	19971204	WO 1997-JP1757	19970522
W: AU, CA, CN, JP, KR, US				
RM: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE AU 9727928	A1	19980105	AU 1997-27928	19970522
EP 914322	A1	19990512	EP 1997-922166	19970522
R: CH, DE, ES, FR, GB, IT, LI				
JP 2000511173	T2	20000829	JP 1997-542017	19970522
ZA 9710603	A	19980625	ZA 1997-10603	19971125
US 6069162	A	20000530	US 1999-147317	19990528
PRIORITY APPLN. INFO.:				
		AU 1996-84	A	19960527
		AU 1996-4219	A	19961216
		WO 1997-JP1757	W	19970522

OTHER SOURCE(S): MARPAT 128:48225
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I: R1 = indolyl, benzofuranyl; R2 = H, lower alkylthio(lower)alkyl, II (wherein R5 = H, lower alkoxy, halo); R3 = H, quinolyl, (un)substituted Ph; R4 = H, (un)esterified COOH; X = S, NR6 [wherein R6 = H, lower alkyl, III (R7 = lower alkyl, lower alkoxy)]) which possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, and the like, were prepared. Thus, reaction of 1-methyl-2-hydroxymethyl-5-phenylimidazole with indole-2-carboxylic acid in the presence of 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-

L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ethylcarbodiimidazole.HCl in CH₂Cl₂ afforded the title compd. IV.
Representative compd. V showed 100% inhibition of NO prodn. at 10⁻⁵ M.
IT 200070-02-6P 200070-05-9P 200070-08-2P
200070-11-7P 200070-14-0P 200070-17-3P
200070-20-8P 200070-23-1P 200070-26-4P
200070-32-2P 200070-38-8P 200070-47-9P
200070-52-6P 200070-57-1P 200070-60-6P
200070-63-9P 200070-66-2P 200070-69-5P
200070-72-0P 200070-75-3P 200070-78-6P
200070-82-2P 200070-85-5P 200070-88-8P
200070-91-3P 200070-94-6P 200070-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of new indolyl and benzofuranyl carboxamides as
inhibitors of
nitric oxide production)
RN 200070-02-6 CAPLUS
CN 1H-Imidazole-4-carboxylic acid, 2-(1-amino-2-phenylethyl)-1-methyl-5-
phenyl-, ethyl ester, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-05-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α-[(4-methoxyphenyl)methyl]-1-methyl-5-
phenyl-, (αS)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-08-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)-α-[(4-
methoxyphenyl)methyl]-1-methyl-, (αS)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.


L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 200070-20-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-chlorophenyl)-1-methyl-α-
(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-23-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-methyl-5-(4-methylphenyl)-α-
(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-26-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-[(4-chlorophenyl)methyl]-1-methyl-5-
phenyl-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-32-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-methyl-5-phenyl-α-(phenylmethyl)-,
(S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 200070-11-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-methyl-5-[4-(methylthio)phenyl]-α-
(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-14-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)-α-[(4-
chlorophenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-17-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)-1-methyl-α-
(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 200070-38-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-methyl-α-(phenylmethyl)-5-(6-
quinoliny)-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-47-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-methoxyphenyl)-1-methyl-α-
(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.



RN 200070-52-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 1-methyl-α-[2-(methylthio)ethyl]-5-
phenyl-, (S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 200070-57-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 5-(4-ethoxyphenyl)-1-methyl-α-
(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 200070-60-6 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-ethylphenyl)-1-methyl- α -(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-63-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(2-chlorophenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200070-66-2 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -[(4-methoxyphenyl)methyl]-1-methyl-5-(4-methylphenyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-69-5 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-chlorophenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 200070-82-2 CAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-(1-amino-2-phenylethyl)-5-(4-bromophenyl)-1-methyl-, ethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-85-5 CAPLUS
 CN 1H-Imidazole-2-methanamine, 1-methyl-5-phenyl- α -(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 200070-88-8 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-bromophenyl)- α -[(4-ethoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200070-91-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -[(4-bromophenyl)methyl]-5-(4-methoxyphenyl)-1-methyl-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 200070-72-0 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(3-chlorophenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-75-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-fluorophenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-78-6 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-ethoxyphenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 200070-94-6 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -[(4-ethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200070-97-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, 5-(4-methoxyphenyl)- α -[(4-methoxyphenyl)methyl]-1-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:538112 CAPLUS
 DOCUMENT NUMBER: 127:242797
 TITLE: Design, synthesis and structure-activity relationship studies of novel 4,4-bis(trifluoromethyl)imidazolines as Acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents
 AUTHOR(S): Li, Hui-Yin; DeLucca, Indawati; Boswell, George A.; Billheimer, Jeffrey T.; Drummond, Spencer; Gillies, Peter J.; Robinson, Candy
 CORPORATE SOURCE: Exp. Stn., DuPont Merck Pharm. Co., Wilmington, DE, 19880-0500, USA
 SOURCE: Bioorganic & Medicinal Chemistry (1997), 5(7), 1345-1361
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Novel 4,4-bis(trifluoromethyl)imidazolines have been found to be the potent acyl-CoA cholesterol acyltransferase (ACAT) inhibitors. ACAT is responsible for cholesterol esterification in the intestine, liver, and the arterial wall. These novel imidazolines also inhibit cholesterol ester formation in the macrophage. Several compds. have shown potent serum cholesterol-lowering activity in several animal models.
 Para-substitution of the 2-Ph is critical for in vitro and in vivo activity. The 4,4-bis(trifluoromethyl)imidazolines with a para-cyano group on 2-Ph and a 4-alkylcyclohexyl amide as the side-chain at the 5-position possess the most potent inhibitory activity in this series. Based on biochem. studies, this series acts as a competitive inhibitor with respect to cholesterol binding at the enzyme, which distinguishes it from most of the ACAT inhibitors discovered to date. Preliminary biol. studies supported by X-ray crystal structures, mol. modeling, and structure-activity relationship (SAR) studies suggest that this series may be a cholesterol mimic.
 IT 81659-38-3 81659-40-7 195812-64-7
 RL: RCT (Reactant); RACT (Reactant or reagent) (synthesis and structure-activity relationship studies of 4,4-bis(trifluoromethyl)imidazolines as Acyl-CoA: cholesterol acyltransferase inhibitors)
 RN 81659-38-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-1-methyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 81659-40-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 195812-64-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4,5-bis(4-chlorophenyl)-1-methyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



L5 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L5 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:466542 CAPLUS
 DOCUMENT NUMBER: 125:221708
 TITLE: Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere
 AUTHOR(S): Chen, Jian Jeffrey; Zhang, Yiping; Hammond, Scott; Dawdney, Nolan; Ho, Teresa; Lin, Xiaohong; Browner, Michel F.; Castelano, Arlindo L.
 CORPORATE SOURCE: Roche Bioscience, Inflammatory Disease Business Unit, Palo Alto, CA, 94304, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(13), 1601-1606
 CODEN: BMECEP; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A novel series of hydroxamate-based inhibitors of matrix metalloproteinases containing benzimidazole and imidazole heterocycles as amide bond isosteres have been prepared. Potent inhibition (in the low nanomolar range) and selectivity (> 100-fold) can be attained with inhibitors containing only one amide bond. X-ray crystal structures of matrilysin (MMP-7) with two different inhibitors bound confirm that imidazole is an excellent amide bond isostere.
 IT 167983-80-4DP, derivs.
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 167983-80-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:335557 CAPLUS
 DOCUMENT NUMBER: 125:86556
 TITLE: A facile synthesis of 4,4-bis(trifluoromethyl)imidazolines via a novel oxidative imidazole rearrangement
 AUTHOR(S): Li, Hui-Yin; Delucca, Indawati; Drummond, Spence; Boswell, George A.
 CORPORATE SOURCE: Chemical Sciences Division Experimental Station, The DuPont Merck Pharmaceutical Company, Wilmington, DE, 19880-0353, USA
 SOURCE: Heterocycles (1996), 43(5), 937-940
 CODEN: HETCYM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 125:86556
 GI




AB Oxidation of 4,5-bis(4-fluorophenyl)-1-methyl- α,α -bis(trifluoromethyl)-1H-imidazole-2-methanamine (I) with singlet oxygen or m-chloroperbenzoic acid gave novel 4,4-bis(trifluoromethyl)imidazoline II in 69% yield via a unique oxidative ring opening and subsequent acid catalyzed dehydrocyclization. II had activity as ACAT inhibitor (IC50 20 μ M) and as HMG-CoA reductase inhibitor (IC50 2.5 μ M).
 IT 81659-40-7
 RL: RCT (Reactant); RACT (Reactant or reagent)


L5 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of bis(trifluoromethyl)imidazolyldene)benzamides via oxidative rearrangement of bis(trifluoromethyl)imidazolemethanamine)
 RN 81659-40-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 81659-38-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bis(trifluoromethyl)imidazolyldene)benzamides via oxidative rearrangement of bis(trifluoromethyl)imidazolemethanamine)
 RN 81659-38-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-1-methyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:265571 CAPLUS
 DOCUMENT NUMBER: 125:26006
 TITLE: Novel 4,4-bis(trifluoromethyl)imidazolines as stereospecific and orally active acyl CoA: cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents
 AUTHOR(S): Boswell, George A.; Li, Hui-Yin; Delucca, Indawati; Billheimer, Jeffrey T.; Drummond, Spencer; Gillies, Peter J.; Robinson, Candy
 CORPORATE SOURCE: DuPont Merck Pharmaceutical Co., Chem. Sci. Div., Wilmington, DE, 19880-0353, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(7), 885-8
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A new class of very potent, systemically-active ACAT inhibitors based on a 4,4-bis(trifluoromethyl)imidazoline ring has been discovered. I and its R-enantiomer exhibited very potent oral activities in lowering the serum cholesterol in the animals.
 IT 81659-38-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction: bis(trifluoromethyl)imidazolines as stereospecific and orally active acyl CoA-cholesterol acyltransferase inhibitors and antihypercholesterolemic agents, and their preparation)
 RN 81659-38-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-1-methyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L5 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 1995:804314 CAPLUS
 DOCUMENT NUMBER: 123:228900
 TITLE: Preparation of azole-fused peptides as substance P antagonists and analgesics.
 INVENTOR(S): Morgan, Barry A.; Gordon, Thomas D.; Hansen, Phillip E.; Singh, Jasbir
 PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
 SOURCE: U.S., 34 pp. Cont. of U.S. Ser. No. 131,706, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5378803	A	19950103	US 1992-912949	19920710
PRIORITY APPLN. INFO.:				
			US 1992-912949	B1 19920710
			US 1987-131706	19871211


OTHER SOURCE(S): MARPAT 123:228900
 GI



AB Title compds. [I: Q1 = Pro, bond; Q2 = Pro, D-Trp, bond; Q3 = Pro, D-Trp, Phe, (R)-(2,3,4,9-tetrahydro)-1H-pyrido[3,4-b]indol-2-yl-3-carbonyl, bond;
 Q4 = Pro, D-Trp, Phe, bond; Q5 = D-Trp, Phe, bond; Q6 = Leu, Met, bond;
 Q7 = Phe, N-MePhe, Met, bond; R1 = H, Z, BOC; R2 = H; R3 = Me2CH, Me2CHCH2, H2N(CH2)4, PhCH2, 4-HOC6H4CH2, pyridylmethyl, (1H-indol-3-yl)methyl; R2R3 = atoms to form 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2,3-diyl; R5 = H.


L5 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 167983-80-4 CAPLUS
 CN 1H-imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 OH or alkali metal salt thereof, MeO, EtO, amino, etc.; X = oxa thia, imido; Y = oxo, H2; n = 0,1; starred center is L or D; with a proviso), were prepd. Thus, title compd. (If: starred center has D-configuration), prepd. via thionation of Z-D-Trp-NH2 with P2S5 and cyclocondensation of the product with Et 3-chloro-2-oxo-3-phenylpropionate, antagonized substance P in the guinea pig ileum test with pA2 = 7.3, and in the mouse acetylcholine-induced writhing test showed intrathecal ED50 = 0.78 μ g/mouse.
 IT 167983-25-7p 167983-29-1p 167983-80-4p
 RN 167983-25-7 CAPLUS
 CN L-Phenylalaninamide, N-[[[2-[1-amino-2-(1H-indol-3-yl)ethyl]-5-phenyl-1H-imidazol-4-yl]carbonyl]-D-tryptophyl-L-leucyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167983-29-1 CAPLUS
 CN 1H-imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

L5 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:255610 CAPLUS
 DOCUMENT NUMBER: 116:255610
 TITLE: Preparation of bis(trifluoromethyl)imidazolines as antihypercholesterolemic and antiatherosclerotic agents
 INVENTOR(S): Billheimer, Jeffrey Thomas; Boswell, George Albert, Jr.; De Lucca, Indawati; Drummond, Spencer, Jr.; Gillies, Peter John; Trzaskos, James Michael
 PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9119476	A1	19911226	WO 1991-US3854	19910531
W: AU, CA, JP, KR, US ES, FR, GB, GR, IT, LU, NL, SE DE, DK, AA				
CA 2084399	AA	19911206	CA 1991-2084399	19910531
AU 9181943	A1	19920107	AU 1991-81943	19910531
AU 650026	B2	19940609		
EP 536316	A1	19930414	EP 1991-913532	19910531
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05507496	T2	19931028	JP 1991-512272	19910531
ZA 9104285	A	19930224	ZA 1991-4285	19910605
US 5428041	A	19950627	US 1992-836323	19920304
PRIORITY APPLN. INFO.:				
			US 1990-533565	A2 19900605
			WO 1991-US3854	A 19910531

OTHER SOURCE(S): MARPAT 116:255610
 GI




AB Title compds. I [Ar1 = (substituted) Ph, C1-10 alkyl, (substituted) C3-7 cycloalkyl; Q = O, XR2: X = N, CH, CHR6, NR6, S; R6 = H, C1-3 alkyl, alkenyl, alkynyl; W = C, CH; Y = N, NR7; R7 = H, C1-3 alkyl; Z = C, CH; dotted line = optional bond; R1 = H, C1-3 alkyl, alkenyl, alkynyl; R2 =

L5 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (substituted) C4-15 alkyl, -C4-15 alkenyl, -C4-15 alkynyl, COR3, COAR, CH2AR, CO2AR, etc.; R3 = (substituted) C1-15 alkyl, -C2-15 alkenyl, -C2-15 alkynyl; Ar = (substituted) Ph, etc.; with provisos were prep. as acetyl
 CoA cholesterol acyl transferase (ACAT) inhibitors. Thus, treatment of a chloroform soln. of α,α -bis(trifluoromethyl)-4,5-bis(4-fluorophenyl)-1-methyl-1H-imidazole-2-methanamine with m-chloroperbenzoic acid followed by reflux gave title compd. II in 68% yield. II had IC50
 of 20 μ M in vitro against ACAT in hepatic microsomes. Formulations of I were prepd.
 IT 81659-38-3 81659-41-8 139982-76-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of antihypercholesterolemic and antiatherosclerotic agents)
 RN 81659-38-3 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-1-methyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 81659-41-8 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-1-methyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 139982-76-6 CAPLUS

L5 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1987:176380 CAPLUS
 DOCUMENT NUMBER: 106:176380
 TITLE: Antihypertensive alkyl(phenyl)imidazoles, thiazoles and oxazoles
 INVENTOR(S): Carini, David J.; Wexler, Ruth R.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
 SOURCE: U.S., 13 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4632930	A	19861230	US 1984-676938	19841130

 <->
 PRIORITY APPLN. INFO.: US 1984-676938 19841130
 OTHER SOURCE(S): CASREACT 106:176380; MARPAT 106:176380
 GI




AB The title compds. [I; R1 = C3-7 cycloalkyl, cycloalkenyl, halo-(un)substituted alkyl, alkenyl, alkynyl; R2 = alkoxy, MeCO, cyano, NO2, R6S(O)m; R3, R4 = CF3, CF2H, CF2Cl, CFCl2, CF3CF2, CF3CF2CF2; R5 = R7O, R7NH; R6 = alkyl; R7 = H, alkyl; X = NH, S, O; m = 0-2] were prepared
 as antihypertensives. PhSMe was acylated under Friedel-Crafts conditions with Me2CHCH2COCl to give 82.5% Me2CHCH2COCl-4. This was brominated (95%) and cyclocondensed with HCONH2 to give 42% of an imidazole derivative
 which was N-alkylated with EtOCH2CH2 and underwent substitution with (CF3)2CO to give 59% I (R1 = Me2CH; R2 = MeS; R3 = R4 = CF3; R5 = OH; X = NH) (II). In rats 0.18 mg II/kg orally reduced blood pressure 30 mmHg. Capsules were prepared each containing active ingredient 50, lactose 175, talc 24, and Mg stearate 6 mg.
 IT 107807-53-4P 107807-54-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as antihypertensive)
 RN 107807-53-4 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(1-methylethyl)-5-[4-(methylthio)phenyl]- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-imidazole-2-methanamine, 1-methyl-4,5-bis(4-methylphenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 107807-54-5 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(1-methylethyl)-5-[4-(methylsulfonyl)phenyl]- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1985:78883 CAPLUS
 DOCUMENT NUMBER: 102:78883
 TITLE: Antiinflammatory and/or analgesic imidazoimidazoles
 INVENTOR(S): Whitney, Joel G.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
 SOURCE: U.S., 6 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4478845	A	19841023	US 1983-459189	19830119
PRIORITY APPLN. INFO.: US 1983-459189 19830119				
OTHER SOURCE(S): CASREACT 102:78883; MARPAT 102:78883				
GI				




AB Imidazoimidazoles I (R, R1 = pyridyl, (un)substituted Ph; R2 = Me, Et; R3, R4 = CF3, CHF2, CF2Cl, CFCl2, CF2CF3) were prepared. Thus, 4,5-bis(4-fluorophenyl)- α,α -bis(trifluoromethyl)-1H-imidazole-2-methanamine was treated with Ac2O at reflux 40 h to give I (R = R1 = 4-FC6H4, R2 = Me, R3 = R4 = CF3), which had an ED50 of 6.5 mg/kg in the adjuvant arthritic test in rats compared with phenylbutazone, which had an ED50 of 10 mg/kg.
 IT 81659-35-0 81659-40-7 81659-42-9
 RL: RCT (Reactant); RACT (Reactant or reagent) (cyclocondensation of, with acetic anhydride)
 RN 81659-35-0 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1985:6504 CAPLUS
 DOCUMENT NUMBER: 102:6504
 TITLE: Antihypertensive 4,5-diaryl- α -polyfluoroalkyl-1H-imidazole-2-methanamines
 INVENTOR(S): Whitney, Joel G.
 PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
 SOURCE: U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 471,270, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4472422	A	19840918	US 1983-506605	19830624
ZA 8206501	A	19840425	ZA 1982-6501	19820906
AU 8318706	A1	19840315	AU 1983-18706	19830905
PRIORITY APPLN. INFO.: ZA 1982-6501 A 19820906				
US 1983-471270 A2 19830302				
US 1980-109923 19800107				
US 1983-506605 A 19830624				


OTHER SOURCE(S): MARPAT 102:6504
 GI




AB The antihypertensive title compds. I (R, R1 = pyridyl, (un)substituted Ph; R2, R3 = F3C, F2CH, F2CCl, FCCl2, F3CCF2; R4 = H, Cl-3 alkyl) were prepared. Thus, 1-(1-ethoxyethyl)-4-(4-(4-fluorophenyl)-5-(4-methylthiophenyl)-1H-imidazole was treated with BuLi and Me2NCH2CH2NMe2 in THF at -78° and less Me3SiNMe2 was added to give I (R = 4-FC6H4, R1 = 4-MeSC6H4, R2 = R3 = F3C, R4 = H) (II). The antihypertensive ED30 of II in DOCA-rat (p.o.) was 4.6 mg/kg.
 IT 93700-47-1P 93700-48-2P 93700-49-3P
 93700-50-6P 93748-05-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antihypertensive activity of)
 RN 93700-47-1 CAPLUS

09/26/2006


L5 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 81659-40-7 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-42-9 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-methylphenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-5-(4-(methylsulfonyl)phenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 93700-48-2 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-5-(4-methoxyphenyl)- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 93700-49-3 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(4-(methylthio)phenyl)-5-phenyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 93700-50-6 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(4-(methylsulfonyl)phenyl)-5-phenyl- α,α -bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 93748-05-1 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-5-[4-(methylsulfinyl)phenyl]-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 93700-46-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

RN 93700-46-0 CAPLUS
 CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-5-[4-(methylthio)phenyl]-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN
 1983:16691 CAPLUS
 ACCESSION NUMBER:
 DOCUMENT NUMBER:
 TITLE:
 INVENTOR(S):
 PATENT ASSIGNEE(S):
 SOURCE:
 DOCUMENT TYPE:
 LANGUAGE:
 FAMILY ACC. NUM. COUNT:
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4348404	A	19820907	US 1981-271276	19810615
EP 44486	A1	19820127	EP 1981-105392	19810710
EP 44486	B1	19841031		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT 10092	E	19841115	AT 1981-105392	19810710
CA 1144552	A1	19830412	CA 1981-381924	19810716
ZA 8104912	A	19830223	ZA 1981-4912	19810717
DK 8103239	A	19820122	DK 1981-3239	19810720
FI 8102270	A	19820122	FI 1981-2270	19810720
NO 8102484	A	19820122	NO 1981-2484	19810720
AU 8173125	A1	19820128	AU 1981-73125	19810720
ES 504121	A1	19821201	ES 1981-504121	19810720
HU 28493	O	19831228	HU 1981-2114	19810720
HU 185938	B	19850428		
JP 57042675	A2	19820310	JP 1981-113085	19810721
PRIORITY APPLN. INFO.:			US 1980-170871	A2 19800721
			US 1981-271276	A 19810615
			EP 1981-105392	A 19810710

OTHER SOURCE(S): CASREACT 98:16691
 GI

L5 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title imidazolemethanamines I [R, R1 = 2-, 3-, 4-pyridyl, 3,4-R6R7C6H3
 (R6
 = H, Cl, F; R7 = H, F, Cl, Br, NO2, alkyl, alkoxy, dialkylamino, alkylthio, -sulfinyl or -sulfonyl; R6 = R7 = Cl, F); R2, R5 = H, alkyl;
 R3,
 R4 = H, CF3, CHF2, CF2Cl, CFC12, C2F5; R3 = R4 = H, C2F5] were prepared. Thus, treating 10.0 g
 1-(1-ethoxyethyl)-4,5-bis(4-methoxyphenyl)-
 1H-imidazole at -78° with 30 mL 1.6M BuLi and 11.5 g (CF3)2C:NSiMe3 gave 4.6 g I (R = R1 = 4-MeOC6H4, R2 = R5 = H, R3 = R4 = CF3), which gave
 50% reduction of arthritic swelling in rats at 2.0 mg/kg.
 IT 81659-35-0P 81659-38-3P 81659-40-7P
 81659-41-8P 81659-42-9P 81659-43-0P
 81659-44-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and inflammation-inhibiting activity of)
 RN 81659-35-0 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-38-3 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-1-methyl-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 81659-40-7 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-41-8 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-1-methyl-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-42-9 CAPLUS
 CN 1H-imidazole-2-methanamine, 4,5-bis(4-methylphenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 81659-43-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-chlorophenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 81659-44-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-diphenyl-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 81659-45-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 81659-45-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1982:406299 CAPLUS
DOCUMENT NUMBER: 97:6299
TITLE: Antiinflammatory 4,5-diaryl-α-polyfluoroalkyl-1H-imidazole-2-methanamines
INVENTOR(S): Whitney, Joel Gayton
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXKDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 44486	A1	19820127	EP 1981-105392	19810710
EP 44486	B1	19841031		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4348404	A	19820907	US 1981-271276	19810615
AT 10092	E	19841115	AT 1981-105392	19810710
PRIORITY APPLN. INFO.:				
		US 1980-170871	A	19800721
		US 1981-271276	A	19810615
		EP 1981-105392	A	19810710

OTHER SOURCE(S): MARPAT 97:6299
GI




AB Imidazolemethanamines I (R, R1 = pyridyl, Ph, substituted Ph; R2, R3 = H, CF3, CHF2, CF2Cl, CFCl2, CF2CF3; R4, R5 = H, alkyl) were prepared. Thus 1-(1-ethoxyethyl)-4,5-bis(4-methoxyphenyl)-1H-imidazole was treated with (CF3)2C:NSiMe3 to give 36f I (R = R1 = 4-MeOC6H4, R2 = R3 = CF3, R4 = R5 = H) which had an oral ED50 of 2.0 mg/kg in the adjuvant arthritis test.


IT 81659-35-0P 81659-37-2P 81659-40-7P
81659-41-8P 81659-42-9P 81659-43-0P
81659-44-1P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)

RN 81659-35-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 81659-37-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, methylation and inflammation-inhibiting activity of)
RN 81659-37-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 81659-37-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-40-7 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-41-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-1-methyl-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


L5 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 81659-42-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-43-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-chlorophenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 81659-44-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-diphenyl-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L5 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 81659-45-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 81659-45-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-methoxyphenyl)-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 81659-38-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation, methylation, and antiinflammatory activity of)
RN 81659-38-3 CAPLUS
CN 1H-imidazole-2-methanamine, 4,5-bis(4-fluorophenyl)-1-methyl-α,α-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



Andrew Freistein 10/523,337

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	146.41	313.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-20.25	-20.25

STN INTERNATIONAL LOGOFF AT 12:27:24 ON 26 SEP 2006

Andrew Freistein 10/523,337

Connecting via Winsock to STN

Welcome to STN International! Enter x:

x

Welcome to STN International! Enter x:

LOGINID:ssptabfl626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUL 14	FSTA enhanced with Japanese patents
NEWS 14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS EXPRESS	JUNE 30	CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS LOGIN		Welcome Banner and News Items
NEWS IPC8		For general information regarding STN implementation of IPC 8
NEWS X25		X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

Andrew Freistein 10/523,337

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:38:24 ON 26 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:38:33 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

DICTIONARY FILE UPDATES: 25 SEP 2006 HIGHEST RN 908487-18-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10523337\d.str



chain nodes :
12 13 14 17 18 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
3-6 5-12 12-14 12-13 12-17 17-18 18-21 22-23 22-24 22-25 22-26
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 12-14 12-13 18-21 22-23 22-24 22-25 22-26
exact bonds :
3-6 5-12 12-17 17-18
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11

G1:H,Ak

G2:C,O,S,N

G3:OH,[*1]

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 17:CLASS 18:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 H, Ak

G2 C, O, S, N

G3 OH, [01]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:38:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 452 TO ITERATE

100.0% PROCESSED 452 ITERATIONS
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 7765 TO 10315

PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:38:58 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 8709 TO ITERATE

100.0% PROCESSED 8709 ITERATIONS
SEARCH TIME: 00.00.01

48 ANSWERS

L3 48 SEA SSS FUL L1

=> file hcplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'HCPLUS' ENTERED AT 12:39:04 ON 26 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

Andrew Freistein 10/523,337

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 25 Sep 2006 (20060925/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 6 L3

=> d ibib hitstr 1-6


L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:164774 HCAPLUS
 DOCUMENT NUMBER: 144:253902
 TITLE: Preparation of aromatic compounds as modulators of sphingosine-1-phosphate (S1P) receptor activity
 INVENTOR(S): Saha, Ashis K.; Kavarana, Malcolm J.; Evindar, Ghotas;
 PATENT ASSIGNEE(S): Satz, Alexander L.; Morgan, Barry
 SOURCE: Praecis Pharmaceuticals, Inc., USA
 PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020951	A1	20060223	WO 2005-US28914	20050812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006135786	A1	20060622	US 2005-204266	20050812
PRIORITY APPLN. INFO.:			US 2004-601232P	P 20040813
			US 2005-646436P	P 20050121

OTHER SOURCE(S): MARPAT 144:253902
 IT 876912-25-3P 876912-60-6P 876912-82-2P 876913-13-2P
 876913-54-1P 876913-58-5P 876913-60-9P
 876913-61-0P 876913-62-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound: preparation of aromatic compds. as modulators of sphingosine-1-phosphate (S1P) receptor activity)
 RN 876912-25-3 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-[4-(4-propoxyphenoxy)phenyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876912-59-3 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-[4-(4-propoxyphenoxy)phenyl]-, dihydrogen phosphate (ester), (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876912-60-6 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-[4-(4-propoxyphenoxy)phenyl]-, dihydrogen phosphate (ester), (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876912-67-3 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-[4-(4-propoxyphenoxy)phenyl]-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876912-82-2 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)phenyl]- β -methyl-, (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876913-13-2 HCAPLUS
 CN Phosphonic acid, [(3R)-3-amino-3-[4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)phenyl]-1H-imidazol-2-yl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876913-54-1 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)phenyl]- β -methyl-, dihydrogen phosphate (ester), (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876913-58-5 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)-3-(trifluoromethyl)phenyl]- β -methyl-, (BR)- (9CI) (CA INDEX NAME)

09/26/2006


L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 876913-60-9 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)-2-(trifluoromethyl)phenyl]- β -methyl-, dihydrogen phosphate (ester), (BR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876913-61-0 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)-2-(trifluoromethyl)phenyl]- β -methyl-, (BR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876913-62-1 HCAPLUS
 CN 1H-Imidazole-2-propanoic acid, β -amino-4-[4-(2-[1,1'-biphenyl]-4-ylethoxy)-3-(trifluoromethyl)phenyl]- β -methyl-, (RS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 876913-82-5P 876913-83-6P 876913-84-7P
876913-85-8P 876913-86-9P 876914-14-6P
876914-21-5P 876914-22-6P 876914-23-7P
876914-24-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic compds. as modulators of sphingosine-1-phosphate (S1P1) receptor activity)


RN 876913-82-5 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(octyloxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876913-83-6 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(heptyloxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876913-84-7 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[2-fluoro-4-(octyloxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876914-21-5 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(4-phenylbutoxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876914-22-6 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(5-phenylpentyloxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876914-23-7 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(4-phenylbutoxy)phenyl]-, dihydrogen phosphate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876914-24-8 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(5-phenylpentyloxy)phenyl]-, dihydrogen phosphate (ester), (R)- (9CI) (CA INDEX NAME)

09/26/2006


L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 876913-85-8 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[3-fluoro-4-(octyloxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876913-86-9 HCAPLUS
CN 1H-imidazole-2-ethanol, beta-amino-4-[4-(octyloxy)phenyl]-, dihydrogen phosphate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876914-14-6 HCAPLUS
CN 1H-imidazole-2-propanoic acid, beta-amino-4-[4-(octyloxy)phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:589369 HCAPLUS
 DOCUMENT NUMBER: 143:248595
 TITLE: Synthesis of 4(5)-phenylimidazole-based analogs of sphingosine-1-phosphate and FTY720: Discovery of potent S1P1 receptor agonists
 AUTHOR(S): Clemens, Jeremy J.; Davis, Michael D.; Lynch, Kevin R.; Macdonald, Timothy L.
 CORPORATE SOURCE: Department of Chemistry, University of Virginia, Charlottesville, VA, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(15), 3568-3572
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:248595
 IT 654642-54-3P 863482-94-4P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of 4(5)-phenylimidazole-based analogs of sphingosine-1-phosphate and FTY720 as potent S1P1 receptor agonists)
 RN 654642-54-3 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-(4-octylphenyl)- (9CI) (CA INDEX NAME)



RN 863482-94-4 HCAPLUS
 CN 1,3-Propanediol, 2-amino-2-[4-(4-octylphenyl)-1H-imidazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 851511-98-3P 863482-81-9P 863482-83-1P
 863482-88-6P 863482-97-7P 863482-99-9P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis of 4(5)-phenylimidazole-based analogs of

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 863482-83-1 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-(4-octylphenyl)-, (1S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
 CRN 863482-82-0
 CMF C19 H29 N3 O

Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 863482-88-6 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-(4-octylphenyl)-, dihydrogen phosphate (ester), mono(trifluoroacetate) (salt), (1R)- (9CI) (CA INDEX NAME)


CM 1
 CRN 863482-87-5
 CMF C19 H30 N3 O4 P

Absolute stereochemistry.

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 sphingosine-1-phosphate and FTY720 as potent S1P1 receptor agonists)
 RN 851511-98-3 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-(4-octylphenyl)-, dihydrogen phosphate (ester), mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 654642-55-4
 CMF C20 H32 N3 O4 P



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 863482-81-9 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-4-(4-octylphenyl)-, dihydrogen phosphate (ester), mono(trifluoroacetate) (salt), (1S)- (9CI) (CA INDEX NAME)


CM 1

CRN 863482-80-8
 CMF C19 H30 N3 O4 P

Absolute stereochemistry.



L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 863482-97-7 HCAPLUS
 CN 1,3-Propanediol, 2-amino-2-[4-(4-octylphenyl)-1H-imidazol-2-yl]-, mono(dihydrogen phosphate) (ester), monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 863482-99-9 HCAPLUS
 CN 1,3-Propanediol, 2-amino-2-[4-(4-octylphenyl)-1H-imidazol-2-yl]-, mono(dihydrogen phosphorothioate) (ester), monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:405396 HCAPLUS
DOCUMENT NUMBER: 142:463965
TITLE: Preparation of orally available sphingosine
1-phosphate receptor agonists and antagonists
INVENTOR(S): Lynch, Kevin R.; MacDonald, Timothy L.
PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
SOURCE: PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041899	A2	20050512	WO 2004-US36563	20041103
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-516887P P 20031103

OTHER SOURCE(S): MARPAT 142:463965

IT 851512-01-1P 851512-03-3P

RL: PAC (Pharmacological activity); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of orally available sphingosine 1-phosphate receptor

agonists and antagonists)


RN 851512-01-1 HCAPLUS

CN 1,3-Propanediol, 2-amino-2-[4-(4-octylphenyl)-1H-imidazol-2-yl]-, mono(dihydrogen phosphorothioate) (ester), mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 851512-00-0

CMF C20 H32 N3 O5 P



L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 851512-03-3 HCAPLUS

CN 1,3-Propanediol, 2-amino-2-[4-(4-octylphenyl)-1H-imidazol-2-yl]-, mono(dihydrogen phosphorothioate) (ester), mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 851512-02-2

CMF C20 H32 N3 O4 P S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 654642-54-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(Preparation of orally available sphingosine 1-phosphate receptor

agonists and antagonists)

RN 654642-54-3 HCAPLUS

CN 1H-imidazole-2-ethanol, β -amino- β -methyl-4-(4-octylphenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 851511-98-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of orally available sphingosine 1-phosphate receptor

agonists and antagonists)


RN 851511-98-3 HCAPLUS

CN 1H-imidazole-2-ethanol, β -amino- β -methyl-4-(4-octylphenyl)-, dihydrogen phosphorothioate (ester), mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 654642-55-4

CMF C20 H32 N3 O4 P



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:100959 HCAPLUS
DOCUMENT NUMBER: 140:164230
TITLE: Preparation of amino acid derivatives which are active
INVENTOR(S): Lynch, Kevin R.; MacDonald, Timothy L.
PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010949	A2	20040205	WO 2003-US23768	20030730
WO 2004010949	A3	20041007		
W:	AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2533587	AA	20040205	CA 2003-2533587	20030730
AU 2003259296	A1	20040216	AU 2003-259296	20030730
EP 1546110	A2	20050629	EP 2003-772068	20030730
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005222422	A1	20051006	US 2005-523337	20050128
PRIORITY APPLN. INFO.:			US 2002-399545P	P 20020730
			US 2002-425595P	P 20021112
			WO 2003-US23768	W 20030730


OTHER SOURCE(S): MARPAT 140:164230
IT 654642-54-3P, VPC 24241
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid derivs. which are active in sphingosine-1-phosphate signaling)
RN 654642-54-3 HCAPLUS
CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-(4-octylphenyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:31491 HCAPLUS
DOCUMENT NUMBER: 134:100877
TITLE: Preparation of N-imidazolylmethyl carboxamides as nitric oxide production inhibitors
INVENTOR(S): Shima, Ichiro; Ohkawa, Takehiko; Ohne, Kazuhiko; Zenkoh, Tatsuya; Sato, Kentaro
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002387	A1	20010111	WO 2000-JP4302	20000629
W:	JP, US			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
EP 1196407	A1	20020417	EP 2000-940882	20000629
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2003503489	T2	20030128	JP 2001-507824	20000629
PRIORITY APPLN. INFO.:			AU 1999-1425	A 19990705
			WO 2000-JP4302	W 20000629

OTHER SOURCE(S): MARPAT 134:100877
IT 319458-80-5P 319458-88-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-imidazolylmethyl carboxamides as nitric oxide production inhibitors)
RN 319458-80-5 HCAPLUS
CN 1H-Imidazole-2-ethanol, β -amino- α ,1-dimethyl-5-[4-(4-morpholinyl)phenyl]-, trihydrochloride, (aR,(R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 3 HCl


RN 319458-88-3 HCAPLUS

09/26/2006

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 654642-55-4P, VPC 24287
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. which are active in sphingosine-1-phosphate signaling)
RN 654642-55-4 HCAPLUS
CN 1H-Imidazole-2-ethanol, β -amino- β -methyl-4-(4-octylphenyl)-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1H-Imidazole-2-ethanol, β -amino-1-methyl-5-[4-(4-morpholinyl)phenyl]-, (R)-, triacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 319458-87-2
CMF C16 H22 N4 O2

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:424263 HCAPLUS
 DOCUMENT NUMBER: 129:95714
 TITLE: Preparation of new heterocyclic amides as nitric oxide
 INVENTOR(S): production inhibitors
 Yatabe, Takumi; Inoue, Takayuki; Hamashima, Hitoshi;
 Shima, Ichiro; Ohne, Kazuhiko; Yoshihara, Kousei;
 Oku,
 PATENT ASSIGNEE(S): Teruo
 Fujisawa Pharmaceutical Co., Ltd., Japan; Itoh,
 Yoshikuni
 SOURCE: PCT Int. Appl., 533 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827108	A2	19980625	WO 1997-JP4243	19971120
WO 9827108	A3	19980730		
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749680	A1	19980715	AU 1997-49680	19971120
EP 946587	A2	19991006	EP 1997-912529	19971120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001505585	T2	20010424	JP 1998-527528	19971120
ZA 9710603	A	19980625	ZA 1997-10603	19971125
PRIORITY APPLN. INFO.: AU 1996-4219 A 19961216				
AU 1997-5929 A 19970401				
AU 1997-9030 A 19970909				
WO 1997-JP4243 W 19971120				

OTHER SOURCE(S): MARPAT 129:95714
 IT 209527-18-4P 209527-89-9P
 209528-48-3P 209529-02-2P 209529-08-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of new heterocyclic amides as nitric oxide production inhibitors)
 RN 209527-18-4 HCAPLUS
 CN 1H-Imidazole-2-propanamide, β -amino-5-(4-ethoxyphenyl)-1-methyl-N-phenyl-, (RS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209527-57-1 HCAPLUS
 CN 1H-Imidazole-2-propanamide, β -amino-N,1-dimethyl-5-(4-nitrophenyl)-, (RS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209527-89-9 HCAPLUS
 CN 1H-Imidazole-2-ethanol, β -amino-1-methyl-5-(4-nitrophenyl)-, (RR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 209528-48-3 HCAPLUS
 CN 1H-Imidazole-4-carboxylic acid, 2-[(1S)-1-amino-3-oxo-3-(phenylamino)propyl]-1-methyl-5-(4-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 209529-02-2 HCAPLUS
 CN 1H-Imidazole-2-propanamide, β -amino-N,1,3-benzodioxol-5-yl-5-[4-(1H-imidazol-1-yl)phenyl]-1-methyl-, (RS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209529-08-8 HCAPLUS
 CN 1H-Imidazole-2-propanamide, β -amino-5-[4-(1H-imidazol-1-yl)phenyl]-N-(4-methoxyphenyl)-1-methyl-, (RS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Andrew Freistein 10/523,337

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

23.59

190.74

STN INTERNATIONAL LOGOFF AT 12:39:36 ON 26 SEP 2006